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2Abstract 
G protein–coupled receptors (GPCR) represent the largest family of membrane proteins 
in the human genome. Physical association between two different GPCRs is linked to 
functional interactions which generates a novel entity, called heteromer, with specific ligand 
binding and signaling properties. Heteromerization is increasingly recognized to take place in 
the mesocorticolimbic pathway and to contribute to various aspects related to substance use 
disorder. This review focuses on heteromers identified in brain areas relevant to drug addiction. 
We report changes at the molecular and cellular levels that establish specific functional impact 
and highlight behavioral outcome in preclinical models. Finally, we briefly discuss selective 
targeting of native heteromers as an innovative therapeutic option.
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31. Introduction
Drug addiction or Substance Use Disorder (SUD) is a multifactorial disease that 
emerges from the combination of genetic predisposition, socio-economic environment and the 
nature of the drug itself. Addiction develops from initial recreational drug use but also emerges 
following misuse amd/or abuse of prescription drugs after an initial therapeutic use or in 
patients that self-medicate. It progresses towards compulsive drug seeking and consumption 
until this excessive behavior cannot be controlled despite adverse consequences to an 
individual’s social and professional life. In addition, negative emotional states, such as anxiety 
and irritability, characterize abstinence. Therefore, maintaining long-term abstinence is the 
major challenge to be faced by addicts and SUD is now recognized as a chronic relapsing 
neuropsychiatric disorder (Koob and Volkow, 2010). 
All drugs alter dopaminergic tone by promoting activation of the mesocorticolimbic 
pathway. This neurocircuit consists of dopaminergic projections from the ventral tegmental 
area (VTA) to the nucleus accumbens (Nacc), amygdala and prefrontal cortex (PFC). 
Glutamatergic projections from the PFC also contribute to the core regulation process of this 
pathway. Additional brain areas then modulate the activity of this circuit in response to external 
stimuli such as spatial (hippocampus) and non-spatial (amygdala) cues, or internal states 
(amygdala, hypothalamus, raphe nuclei) (Figure 1). Importantly, addiction is now 
acknowledged to also develop in response to behavioral patterns such as gambling or excessive 
food consumption. In these pathologies, endogenous opioid and/or endocannabinoid peptides 
are released that activate their cognate receptor to stimulate the dopaminergic 
mesocorticolimbic pathway as observed for exogenous drugs of abuse (Noori et al., 2016).
Despite common modulation of the mesocorticolimbic pathway, the molecular targets 
of drugs of abuse differ significantly. Opiates, tetrahydrocannabinol (THC) or the 
psychostimulants caffeine or hallucinogen lysergic acid diethylamide (LSD) bind to G protein-
4coupled receptors (GPCR), namely the opioid, cannabinoid, adenosine or serotonin receptors 
respectively. Alcohol mainly targets ligand-gated channels whereas psychostimulants such as 
amphetamines or cocaine modulate the dopamine transporter. Accordingly, pharmacological 
approaches have revealed that SUD is a complex process and that drug induced neuroplasticity 
covers multiple aspects including interactions triggered between different neuromodulatory 
systems. Cross-talk can take place at the molecular level through direct interactions between 
two GPCRs. This gives rise to a novel entity, a heteromer, which is characterized by specific 
ligand binding, signaling and/or trafficking properties. Cross-talk can also occur at the cellular 
level through simultaneous activation of several signaling cascades and at the integrated level 
through concomitant involvement of distinct neuronal circuits. Moreover, interactions can 
simultaneously occur at the three levels adding complexity to the ways in which drugs of abuse 
exert their effects.
Here, we review native heteromers formed by associations of two GPCRs or by 
association of a GPCR with an ion channel, in brain areas related to SUD. We focus on in vivo 
functional alterations and highlight behavioral consequences. We also include data collected 
in co-transfected cells that provide insight into the heteromerization process or add to our 
comprehension of heteromer signaling.  Finally, we briefly address the potential of these 
heteromers as novel therapeutic targets.
2. The concept of heteromerization in GPCRs
All GPCRs have a common architecture made of seven -helical transmembrane 
domains (TM) and possess an extracellular N-terminus and intracellular C-terminus. Specific 
recognition of the ligands takes place in the extracellular N-terminus and loops, but ligand 
binding also requires docking in a pocket within the helical bundle. Binding of an agonist leads 
5to receptor activation which in turn affects interaction with intracellular partners and initiates 
multiple downstream signaling events.
Based on specific structural determinants, GPCRs are usually sorted into five different 
classes with classes A, B, C and  F being expressed in mammals (Fredriksson and Schioth, 
2005). GPCRs exhibit a high propensity to aggregate (Salim et al., 2002), which raised the 
question of criteria for a minimal functional unit. About 20 years ago, functional GABAB 
receptors from class C GPCRs were shown to require mandatory association of GABAB1 and 
GABAB2 receptors to be functional (Jones et al., 1998). Obligatory dimerization has 
subsequently been shown for other class C GPCRs such as the metabotropic glutamate 
receptors or the taste receptors (Rondard et al., 2011). In contrast, several class A GPCRs 
including rhodopsin, 2 adrenergic, neurotensin 1, leukotriene B2 or mu opioid receptors are 
able to bind ligands, activate G proteins and recruit -arrestin or G protein kinases in a 
monomeric form when reconstituted in a lipidic environment (reviewed in (Vischer et al., 
2015)). The ability of a receptor to initiate signaling cascades as a monomeric entity does not 
however preclude interaction with other monomers from the same or a different receptor type 
to form a larger functional complex. For example, two monomers were found associated with 
one heterotrimeric G protein in the case of the serotonin 5HT4 receptor (Pellissier et al., 2011). 
Activation of one monomer was enough to stimulate the G protein but co-activation led to a 
positive cross-talk indicating that this receptor rather functions as a homodimer. Similarly, the 
minimal signaling unit of the dopamine D2 receptor was defined as homodimer. Here again, 
activity was maximal upon agonist binding to one monomer but was modulated by the 
constitutive activity of the second monomer indicating asymmetric functional interaction (Han 
et al., 2009). Whether the minimal functional unit involves a monomer or a homodimer thus 
appears receptor dependent (reviewed in (Ferre et al., 2014)).
6In native tissue, class A GPCRs usually form clusters where they functionally interact 
with the surrounding receptors forming the so-called homomers if only one receptor type is 
present or heteromers if associated with a different receptor/protein (Khelashvili et al., 2010). 
Heteromers have been extensively studied in co-transfected cells using biochemical, 
biophysical, or pharmacological approaches often combined with generation of mutant 
receptors (for reviews see (Fernandez-Duenas et al., 2012; Maggio et al., 2013; Vischer et al., 
2015). Early on, major efforts were invested to overcome technical limitations and validate 
their existence in native tissue. In 2007, the International Union of Basic and Clinical 
Pharmacology defined criteria for validation of heteromer formation in class A GPCRs (Pin et 
al., 2007) comprising three main criteria:
1) There should be evidence for physical association in native tissues or primary cells. 
This can be obtained by co-immunoprecipitation, co-localization with antibody at electron 
microscopic level or energy transfer technologies using labeled ligands or knock-in animals. 
The use of the proximal ligation assay (PLA), developed more recently, is also widely accepted 
as appropriate to detect in situ receptor physical proximity.
2) In native tissues, heteromerization must induce a specific functional property, either 
a new pharmacological profile and/or the activation of a specific transduction cascade, distinct 
from those induced by each receptor expressed alone.
3) Disruption of the physical interaction (knock-out animals, RNAi technology, 
interfering peptide) must drastically alter the specific functional properties assigned to 
heteromers.
In the past years, our understanding of the functional impact of in vivo heteromerization 
has significantly improved and the concept has gained acceptance.  Next to heteromer 
formation involving two class A GPCRs, heteromer formation between class A and class C 
GPCRs or between GPCRs and other proteins such as ion channels have also been reported. 
7This, in turn, has introduced an additional level of complexity in our interpretation of the 
behavioral responses observed upon receptor activation but has also expanded the repertoire of 
tools enabling modulation of cellular activity and physiological pathways. 
3. Modulation of striatal dopaminergic transmission by heteromers
Dopamine transmission in the striatum is central to SUD though modulated in different 
ways by drugs of abuse. Opiates, cannabis and alcohol, impact the core VTA-Nacc 
dopaminergic axis by reducing GABAergic tonic inhibition on dopamine release whereas 
psychostimulants modulate the activity of dopaminergic receptors in the basal ganglia both 
contributing to the reinforcing effect of a drug. In the striatum, medium spiny neurons (MSN) 
play a crucial role in this process by integrating information and propagating it through two 
main output pathways (Figure 2A). The direct striato-nigral pathway projects to the internal 
globus pallidus and substantia nigra (SN) and expresses dopamine D1 receptors together with 
dynorphin and substance P. The indirect striato-pallidal pathway projects to the external globus 
pallidus and expresses dopamine D2 receptors together with enkephalins (Tepper et al., 2007). 
More recently, a third striatal output has been postulated which is composed of a discrete 
neuronal population of the ventral striatum, mostly in the Nacc shell. These neurons co-express 
D1 and D2 receptors, dynorphin, enkephalin, GABA, and glutamate and may project to the SN 
and VTA (Perreault et al., 2012a). Importantly, each pathway expresses a combination of 
postsynaptic GPCRs coupled to inhibitory Gi/o or excitatory Gs subunits, providing the 
opportunity to further modulate neuronal activity through receptor heteromerization (Figure 
2B). 
4. Class A-class A heteromers with established modulatory role in SUD
8Here, we review functional properties of heteromers showing altered expression levels 
upon drug exposure and/or specific impact on behaviors related to SUD (Figure 3).
4.1 Adenosine A2a-dopamine D2 heteromers
Heteromerization of adenosine A2a and dopamine D2 receptors has been extensively 
studied in native tissue. Close physical proximity of A2a and D2 receptors was detected by in 
situ PLA in the striatum of C57BL6/J mice (He et al., 2016; Trifilieff et al., 2011) and 
confirmed in rats by electron microscopy and time-resolved fluorescence resonance energy 
transfer (FRET) (Fernandez-Duenas et al., 2015). Co-internalization was detected upon 
activation by D2 or A2 agonists in SHSY5Y neuroblastoma and in primary striatal neurons 
(Hillion et al., 2002; Huang et al., 2013). Bivalent ligands bound to D2 or A2a receptors with 
higher affinity than the corresponding monovalent control ligands in striatal membranes but 
not in membranes expressing one receptor only suggesting synergistic binding at A2a-D2 
heteromers (Soriano et al., 2009), which supports close physical proximity of A2a and D2 
receptors. 
Remarquably, changes in the extent of physical association between A2a and D2 
receptors were reported in several behavioral paradigms relevant to SUD. Psychostimulants 
induce sensitization of the dopaminergic system and progressively disrupt goal directed 
behaviors in favor of goal insensitive habitual responding (Furlong et al., 2017). This transition 
is facilitated by D1 receptor activation and inhibited by D2 receptors. In the striatum of 
C57BL6/J mice, A2a-D2 heteromers were more abundant in the dorsolateral than in the 
dorsomedial striatum in basal conditions (He et al., 2016; Trifilieff et al., 2011). However, in 
situ PLA revealed higher signal in the dorsomedial and dorsolateral striatum in a paradigm of 
habit formation (random interval training) whereas it remained unchanged in a paradigm of 
goal directed behavior (random ratio training) (He et al., 2016). This suggests that A2a-D2 
9heteromers participate in the negative regulation of D2 signaling in the striatum and contribute 
to the control of abnormal habit formation taking place during drug addiction especially during 
relapse. This view is in line with accelerated habit formation following methamphetamine 
sensitization observed when D2 receptors are pharmacologically blocked before instrumental 
learning (Nelson and Killcross, 2013). Moreover, these animals were unable to inhibit 
responding in extinction and reacquisition phases even when they acquired an aversion to the 
reinforcer (Nelson and Killcross, 2013). A2a-D2 heteromers may therefore also contribute to 
the development of compulsive behaviors. 
In a model of cocaine self-administration, in situ PLA revealed increased A2a-D2 
heteromers in the Nacc shell but not in the dorsal striatum of rats (Borroto-Escuela et al., 2017). 
Injection of the A2a TM V peptide in the Nacc disrupted the A2a-D2 heteromers as shown by 
decreased in situ PLA signal (Borroto-Escuela et al., 2018). It also suppressed the inhibitory 
effect of the A2a agonist CGS21680 on cocaine self-administration (Borroto-Escuela et al., 
2018), in agreement with reports demonstrating that reinstatement of cocaine self-
administration is decreased or favored by A2a agonists or antagonists respectively (O'Neill et 
al., 2012).
Dynamical changes have also been described in a model of voluntary alcohol intake 
(intermittent access to 20% alcohol for at least 12 weeks), which led to higher detection of A2a-
D2 heteromers in the Nacc shell and dorsal striatum by in situ PLA (Feltmann et al., 2018). 
This is in line with the regulation of ethanol’s rewarding effect in mice by A2a receptors 
expressed in striatopallidal neurons (Arolfo et al., 2004). Ethanol interacts directly with the 
adenosine system by blocking nucleoside transporters in the cell membrane. More specifically, 
ethanol selectively inhibits the type 1 equilibrative nucleoside transporter (ENT1) leading to 
decreased levels of striatal adenosine (Dunwiddie and Masino, 2001). Using ENT1 knock-out 
mice to mimic reduced adenosine availability, Nam et al. (2013) showed that dampening A2a 
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signaling in the dorsomedial striatum promoted ethanol seeking behaviors through decreased 
CREB activity and enhanced goal-oriented behaviors, hence contributing to excessive ethanol 
drinking (Nam et al., 2013). Ethanol also decreased ENT1 expression in the Nacc where 
reduced levels of adenosine could contribute to ethanol dependence and tolerance (Nam et al., 
2013). In line with these observations, mice lacking A2a showed reduced sensitivity to the 
hypnotic effects of alcohol, increased alcohol consumption and reduced alcohol-withdrawal 
seizures (El Yacoubi et al., 2001). At the level of A2a-D2 heteromers, reduced A2a activity 
would decrease D2 signaling thereby contributing to reduce alcohol withdrawal symptoms but, 
at the same time, increasing alcohol consumption. Interestingly, the A2a antagonist caffeine is 
often present as adulterant in the preparation of illicit drugs and in energy drinks consumed in 
combination with alcohol or other psychostimulants. A2a-D2 heteromers could thus mediate 
caffeine stimulant effects that would mask some of the acute intoxicating effects of ethanol and 
promote ethanol seeking behavior (reviewed in (Ferre, 2016).
At the molecular level, the domains at the interface of the two receptors have been 
widely explored in vitro using a variety of approaches including mutagenesis, receptor 
chimeras, glutathione S transferase pull-down coupled to mass spectrometry and molecular 
modeling. The transmembrane domain TM V and third intracellular loop IL3 of the D2 receptor 
were identified as part of the contact area and were required to observe antagonistic 
pharmacological interactions (Torvinen et al., 2004) (Borroto-Escuela et al., 2010). More 
precisely, the arginine cluster 217RRRRKR222 present in the third intracellular loop IL3 of 
both short D2S and long D2L receptor isoforms form electrostatic interactions with two aspartate 
residues (D401A, D402a) and the phosphorylated S374 residue in the A2a C-terminus (Borroto-
Escuela et al., 2010; Ciruela et al., 2004).
Recently, a functional heterotetramer composed of D2-D2 and A2a-A2a homomers has 
been proposed to integrate the experimental data collected over the years (Borroto-Escuela et 
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al., 2016; Fuxe et al., 2010; Navarro et al., 2014; Taura et al., 2017) and, in particular, the 
psychostimulant effects of the A2a antagonist caffeine (Ferre et al., 2018) (Figure 4). In the 
heterotetramer, the transmembrane domain TM VI is present at the interface between A2a-A2a 
or D2-D2 receptor homomers and transmembrane domains IV and V contribute to the A2a-D2 
heteromeric interface (Navarro et al., 2018b). This macromolecular complex is pre-coupled to 
the partner G proteins and two adenylate cyclase AC5 molecules and undergoes dynamic 
reorganization upon agonist binding (Navarro et al., 2018b).
4.2 Dopamine D2- sigma1 receptor heteromers
The sigma1 receptor was originally wrongly classified within the opioid receptor 
family. The recently solved 3D crystal structure revealed a trimeric protein with one 
transmembrane domain in each protomer. (Schmidt et al., 2016). This ubiquitous protein 
intervenes in various cellular functions, is predominantly located in the endoplasmic reticulum 
(ER) but has also been detected at the plasmalemma and in synaptosomal fractions (recently 
reviewed in (Sambo et al., 2018)). In addition, the sigma1 receptor has an affinity of about 
2M for cocaine and metamphetamine in rodent brain tissue (Matsumoto et al., 2002; Nguyen 
et al., 2005).
Physical proximity between the postsynaptic long isoform of the D2 receptor (D2L) and 
the sigma1 receptor was identified by in situ PLA and co-immunoprecipitation in the mouse 
striatum (Navarro et al., 2013). In a protocol of cocaine self-administration, dopamine D2-
sigma1 proximity was increased in the rat Nacc shell and decreased in the dorsal striatum as 
shown by in situ PLA (Borroto-Escuela et al., 2017). Since cocaine similarly affected A2a-D2 
and D2-sigma1 heteromers in the two regions, one can postulate that the three proteins associate 
into larger A2a-D2-sigma1 heterocomplexes. Interestingly, direct action of 150 M cocaine in 
CHO cells devoid of dopamine transporter but endogenously expressing the sigma1 receptor 
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(Mei and Pasternak, 2001) led to decreased BRET signal between co-expressed A2 and D2 
receptors (Marcellino et al., 2010). This strongly suggests that cocaine concentrations 
compatible with those measured in cocaine abusers could affect the conformation of theA2a-
D2-sigma1 heterocomplex. 
From a functional point of view, co-administration of cocaine and the D2/D3 agonist 
quinpirole decreased ERK1/2 phosphorylation in the mouse striatum. In contrast, cocaine did 
not induce ERK1/2 phosphorylation and could not modify the level of ERK1/2 phosphorylation 
induced by quinpirole in sigma1 knock-out mice (Navarro et al., 2013). Moreover, in the 
presence of sigma1 antagonists (PD144418 or BD1063), cocaine effects were reduced, and 
cocaine failed to amplify the effects of the agonist quinpirole on K+ evoked dopamine and 
glutamate release from striatal synaptosomes (Beggiato et al., 2017; Navarro et al., 2013). 
Altogether, data therefore support a functional role for D2-sigma1 heteromers in the effects of 
cocaine. 
Expression of D2-sigma1 heteromers is also modulated by chronic alcohol suggesting 
a more general implication in SUD. In a model of voluntary alcohol consumption with 
intermittent access to 20% ethanol, a decrease in PLA signal for D2-sigma1 heteromers was 
observed in the dorsal striatum where it was paralleled by a decrease in D2-D2 homomers and 
an increase in A2a-D2 heteromers (Feltmann et al., 2018). 
4.3 Dopamine D1 - dopamine D2 heteromers
In the basal ganglia, the strict separation in D1 and D2 receptor expression patterns has 
been challenged by the description of a subset of striatal MSNs co-expressing D1 and D2 
receptors, dynorphin, enkephalin, GABA and glutamate (Hasbi et al., 2011) (Perreault et al., 
2012b). 
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Heteromerization of D1 and D2 dopamine receptors was then hypothesized. To support 
this view, S. George and collaborators accumulated evidence of D1-D2 physical proximity. 
First, FRET signal was detected on primary striatal cultures between secondary antibodies 
coupled to the AlexaFluor 350 to localize D2 receptors and secondary antibodies coupled to 
the AlexaFluor 488 to localize D1 receptors suggesting co-localization within the same 
membrane domains (Verma et al., 2010). Using FRET efficiency, the proximity of D1 and D2 
receptors was estimated to 5-7 nm in clusters located at the surface of MSNs in the Nacc core 
(Hasbi et al., 2009; Perreault et al., 2016). In vivo D1-D2 physical proximity was also confirmed 
by in situ FRET approaches in the rat striatum (Hasbi et al., 2018). Co-immunoprecipitation 
from striatal rat brain (Hasbi et al., 2009; Lee et al., 2004) and human striatum (Pei et al., 2010) 
further supported close receptor proximity. More recently, endogenous D1-D2 heteromers were 
visualized using in situ PLA in primary striatal cultures and Nacc from rat (Perreault et al., 
2016) as well as in the Nacc shell from the long-tail macaque (Perreault et al., 2016; Rico et 
al., 2017). More specifically, about 30% of the MSNs in the rat Nacc shell and more than 20% 
in the rat Nacc core expressed D1-D2 heteromers at the cell surface versus only 5% of the MSNs 
in the dorsal striatum as revealed by in situ PLA with labeled primary antibodies (Hasbi et al., 
2018). Using the same approach, no D1-D2 heteromers were detected in the mouse striatum of 
mice deficient for either receptor (Hasbi et al., 2018). At the molecular level, heteromerization 
would take place between two adjacent arginine residues located on the D2 third intracellular 
loop IL3 and two adjacent glutamic acid residues located on the D1 C-terminal tail (O'Dowd et 
al., 2012). Accordingly, a TAT-D1 peptide encoding the critical portion of the D1 C-terminus 
disrupted D1-D2 co-immunoprecipitation (Perreault et al., 2016) and abolished the PLA signal 
(Hasbi et al., 2018) in the rat striatum. 
Functionally, D1-D2 heteromers would specifically signal through Gq/11 leading to 
CAMKII activation, intracellular calcium release and increased BDNF expression when co-
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activated by the D1 agonist SKF81297 and the D2 agonist quinpirole or when activated by the 
selective D1-D2 agonist SKF83959 (Hasbi et al., 2009; Lee et al., 2004; Perreault et al., 2016; 
Rashid et al., 2007). Activation of this signaling cascade was disrupted by the TAT-D1 peptide 
encoding the critical portion of the D1 C-terminus thereby establishing dependence on D1-D2 
receptor interaction (Perreault et al., 2016). Increased BDNF expression suggests an impact on 
maturation and differentiation of striatal neurons which could account for drug-induced 
plasticity.
Recently, the role of D1-D2 heteromerization on several behavioral outputs related to 
cocaine consumption was uncovered using disruption of D1-D2 heteromers by the TAT-D1 
peptide in the rat striatum (Hasbi et al., 2018; Perreault et al., 2016). This approach provided 
convincing evidence that activation of D1-D2 heteromers by the D1-D2 agonist SKF83959 
blocked acquisition and expression of cocaine induced CPP whereas disruption of striatal D1-
D2 heteromers potentiated conditioned place preference to cocaine (Hasbi et al., 2018; Perreault 
et al., 2016). Similarly, behavioral sensitization induced by repeated exposure to cocaine, 
which is characterized by an augmented locomotor response to a subsequent psychostimulant 
challenge injection, was abolished by the D1-D2 agonist SKF83959 and potentiated by the 
disruption of striatal D1-D2 heteromers (Hasbi et al., 2018; Perreault et al., 2016). Moreover, 
activation of D1-D2 heteromers by the D1-D2 agonist SKF83959 abolished cocaine self-
administration and reinstatement to cocaine seeking whether promoted by drug priming or cue 
association (Hasbi et al., 2018). Again, disrupting D1-D2 physical interactions led to an 
opposite phenotype with potentiation of both drug self-administration and reinstatement (Hasbi 
et al., 2018). Western blot and immunohistochemical analyses in the NAcc revealed that 
activation of the D1-D2 heteromer likely counteracted cocaine-induced ERK phosphorylation 
and Fos B accumulation and reduced cocaine evoked field potentials signals by increasing 
the phosphorylation of DARPP32 at the Thr75 residue (Hasbi et al., 2018).
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Interestingly, D1-D2 heteromer expression increases with age as it is less abundant in 
the caudate putamen and in the Nacc shell, but not in the Nacc core, of juvenile rats compared 
to adults (Perreault et al., 2010; Perreault et al., 2012b; Perreault et al., 2016). This increase in 
expression was paralleled by increased Gq coupling in 8-month-old rats compared to 3-
month-old animals despite no change in individual receptor expression (Rashid et al., 2007). 
Data therefore suggest a shift towards D1-D2 Gq coupling with age and lower D1-D2 tonic 
inhibition in juvenile animals. This may account for the increased susceptibility to cocaine’s 
behavioral effects observed in adolescents (Spear, 2016) and is in line with the observation that 
behavioral sensitization to psychostimulants such as cocaine requires activation of both D1 and 
D2 receptors (Capper-Loup et al., 2002) and CAMKII (Pierce et al., 1998) in the Nacc.
Importantly, the implication of D1-D2 heteromers is not restricted to cocaine but extends 
to natural reinforcers. Indeed, activation of D1-D2 heteromers by the D1-D2 agonist SKF83959 
reduced sucrose preference in a two-bottle free choice paradigm whereas heteromer disruption 
with the TAT-D1 peptide had the opposite effect (Hasbi et al., 2018). In addition, in a paradigm 
of restricted food access, activation of D1-D2 heteromers reduced the motivation to seek and 
consume palatable food (Hasbi et al., 2018).
4.4 Mu opioid-dopamine D1 heteromers
Co-immunoprecipitation of mu opioid and dopamine D1 receptors in striatal 
membranes from wild type, but not from D1 or mu receptor knock-out mice, established the 
physical proximity of the two receptors (Tao et al., 2017). The D1 antagonist SCH23390 
reduced mu opioid receptor signaling as revealed by reduced G protein activation, decreased 
ERK1/2 phosphorylation and less c-Fos induction in wild type but not D1 knock-out mice (Tao 
et al., 2017). These data are indicative of the cross-antagonism exerted by D1 antagonists on 
mu opioid signaling. Accordingly, chronic systemic co-administration of the D1 antagonist 
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SCH23390 and the mu agonist morphine reduced morphine induced hyperlocomotion, 
sensitization acquisition and expression (Tao et al., 2017). Systemic administration or local 
infusion in the Nacc of the D1 antagonist SCH23390 also decreased expression of the 
locomotor sensitization to the mu agonists morphine and DAMGO (Tao et al., 2017). Similarly, 
morphine or DAMGO induced  locomotor sensitization was markedly decreased upon intra 
Nacc injection of an ERK inhibitor (Tao et al., 2017). D1 impact was independent of 
dopaminergic transmission from the VTA as it was also observed in rats with 6-OHDA lesion 
in the NAcc (Tao et al., 2017). Finally, no locomotor sensitization to morphine was observed 
in knock-out mice deficient for the D1 receptor (Tao et al., 2017). Altogether, data establish 
that mu-D1 heteromers play a critical role in opiate hyperlocomotion and locomotor 
sensitization.
4.5 Mu-delta opioid heteromers
Mapping mu and delta opioid receptors in the brain using double fluorescent knock-in 
mice revealed co-expression in discrete neuronal populations located in subcortical networks 
essential for survival, including the perception and processing of aversive stimuli (Erbs et al., 
2015). Evidence of close physical proximity at the supraspinal level included detection with 
mu-delta selective antibodies (Gupta et al., 2010), mu-delta co-immunoprecipitation in the 
hippocampus (Erbs et al., 2015) and antinociceptive activity upon  intracerebroventricular 
(i.c.v.) injection of MDAN-21, a bivalent ligand bridging the mu agonist oxymorphone and the 
delta antagonist naltrindole (Daniels et al., 2005). Direct physical interaction was shown in the 
Nacc through disruption by a sequence corresponding to the delta carboxy tail (Kabli et al., 
2013), and was also established in the spinal cord through disruption by a peptide 
corresponding to the mu transmembrane domain TM I (He et al., 2011), and in DRGs through 
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disruption with a peptide corresponding to the delta second intracellular loop IL2 (Xie et al., 
2009). 
Immunohistochemical detection with mu-delta specific antibodies revealed that chronic 
morphine treatment increased mu-delta heteromer expression in regions associated with the 
mesocorticolimbic pathway such as the VTA, Nacc, striatum, PFC, hippocampus and, 
hypothalamus (Gupta et al., 2010),  pointing to a modulatory role in SUD.  Of note, chronic 
morphine treatment enhanced delta opioid receptor expression at the cell surface through a mu 
opioid receptor dependent pathway (reviewed (Gendron et al., 2015)) compatible with mu-
delta heteromer formation in the ER (Décaillot et al., 2008; Xie et al., 2009). Enhanced delta 
opioid receptor expression restricted to the circuit of thermal nociception was also reported in 
the spinal cord in a model of voluntary alcohol consumption (van Rijn et al., 2012) indicating 
that increase in functional delta receptors could be achieved upon consumption of drugs of 
abuse other than morphine. Whether the underlying mechanism relies on mu-delta 
heteromerization however requires further confirmation.
Pharmacological evidence also points to a link between mu-delta heteromers and SUD-
related behaviors. Targeting mu-delta heteromers with the  bivalent ligand MDAN-21 (Daniels 
et al., 2005) or with the biased agonist CYM51010 (Gomes et al., 2013) induced less tolerance 
and physical dependence compared to morphine. This is in line with high mu-delta co-
expression in brainstem nuclei tightly connected to the autonomous system (Erbs et al., 2015) 
that suggests mu-delta modulation of somatic and autonomic symptoms during drug 
withdrawal. Moreover, TAN-67, identified as a mu-delta receptor selective agonist in co-
transfected HEK 293 cells, decreased ethanol but not sucrose consumption in wild type but not 
delta receptor knock-out mice (van Rijn and Whistler, 2009). 
From a functional perspective, occupancy of the binding site of one receptor increased 
ligand binding and signaling to the other receptor in SK-N-SH neuroblastoma cells that 
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endogenously co-express the two receptors (Gomes et al., 2004; Gomes et al., 2011; Gomes et 
al., 2000). Interestingly, the nature of the first ligand did not seem important since an agonist, 
antagonist or inverse agonist induced similar effects. Data therefore suggest that mu-delta 
heteromerization induced cross-allosteric modulation with a positive cooperativity promoted 
upon binding of the first ligand. Heterotetramers formed by association of mu homomers with 
delta homomers have been postulated (Golebiewska et al., 2011), which could accommodate 
bidirectional cross-allosteric modulation as for A2a-D2 heterotetramers (Bonaventura et al., 
2015) (Navarro et al., 2018b).
Co-activation of mu and delta opioid receptors in native tissue also resulted in a positive 
cross-talk. Indeed, increased hyperpolarization was observed in a subset of GABAergic 
neurons in VTA slices upon co-application of the delta antagonist TIPP together with mu 
agonist DAMGO or upon co-application of the mu antagonist CTAP together with the delta 
agonists deltorphin II or DPDPE (Margolis et al., 2017). Given their enhanced expression in 
the VTA of morphine dependent animals ((Gupta et al., 2010), Massotte unpublished), mu-
delta heteromers could thus contribute to increase dopamine release in the Nacc. 
Mu-delta heteromerization also alters G protein coupling. In mu-delta co-transfected 
CHO cells, inhibition of forskolin induced cAMP production was maintained after pertussis 
toxin treatment.  This led a postulate that mu-delta heteromers would no longer signal through 
pertussis toxin sensitive inhibitory Gi/o proteins but would recruit the inhibitory pertussis 
toxin insensitive Gz subunit (George et al., 2000). The Gz subunit is expressed in the 
striatum and also abundant in the hippocampus (Friberg et al., 1998) where extensive mu-delta 
heteromerization is present. Gz is recruited by heroin, morphine, buprenorphine, and 
methadone (Sanchez-Blazquez et al., 2001). Moreover, mu-delta preferential coupling to Gz 
would not be desensitized by chronic morphine administration in the rat striatum and 
hippocampus (George et al., 2000; Kabli et al., 2014) and Gz deficient mice show increased 
19
morphine tolerance (Hendry et al., 2000). These data suggest that Gz dependent mu-delta 
signaling could also play a role in drug addiction.
Heteromerization not only affects G protein-dependent signaling but also alters 
 arrestin-dependent pathways. In neuroblastoma SKNSH endogenously co-expressing mu 
and delta opioid receptors, activation by the mu agonist DAMGO led to a spatio-temporal 
change in the ERK1/2 phosphorylation profile with prolonged activation in the cytoplasmic 
compartment (Rozenfeld and Devi, 2007). In the presence of the delta selective antagonist 
TIPP  the phosphorylation profile reversed to the one observed for the mu opioid receptor 
expressed alone (Rozenfeld and Devi, 2007) as expected if dependent on mu-delta 
heteromerization. The change in ERK1/2 phosphorylation profile was also abolished in the 
presence of -arrestin 2 siRNA (Rozenfeld and Devi, 2007). Efficient recruitment of the -
arrestin 2 dependent signaling pathway was also observed upon activation by the biased mu-
delta agonist CYM51010 (Gomes et al., 2013) that promotes co-internalization of mu and delta 
opioid receptors in primary hippocampal neurons (Derouiche et al., 2018). These results 
suggest increased cytoplasmic signaling by internalized mu-delta heteromers in line with recent 
reports on GPCR signaling from the endosomal compartment (Tsvetanova et al., 2015) and 
indicate changes in the spatiotemporal control of neuronal activity. 
4.6 Mu opioid-Galanin1 heteromers
Mu opioid receptors are widely distributed throughout the brain (Erbs et al., 2015). 
Galanin1 (Gal1) receptors are mostly present in the VTA, Nacc, and SN, suggesting that they 
may contribute to the galanin-mediated regulation of dopamine neurotransmission (Moreno et 
al., 2017). Gal1 receptors are also highly expressed in the locus coeruleus, where they may also 
modulate noradrenergic transmission during opiate withdrawal (Hawes and Picciotto, 2004). 
Physical proximity between the mu opioid and Gal1 receptors was established in co-transfected 
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cell by BRET and bimolecular fluorescent complementation (Moreno et al., 2017). In the VTA, 
the mu antagonist CTOP was able to counteract galanin induced ERK1/2, AKT and CREB 
phosphorylation, a cross-antagonism attributed to mu-Gal1 heteromers (Moreno et al., 2017). 
In addition, galanin could not prevent dopamine release promoted by local infusion of the mu 
agonist endomorphin 1 when mu-Gal1 heteromers were disrupted by injection of a peptide 
corresponding to the mu transmembrane domain TM V (Moreno et al., 2017). This suggests a 
negative cross-talk by which galanin dampens mu opioid receptor signaling. Moreover, 
enhanced ERK activation was observed in the VTA, Nacc and amygdala in galanin knock-out 
mice following acute morphine administration compared to wild type mice (Hawes et al., 
2008). Importantly, conditioned place preference to morphine was abolished in galanin knock-
out mice (Hawes et al., 2008). These results therefore substantiate galanin-dependent 
modulation of the reinforcing properties of opiates. In humans, the single nucleotide 
polymorphism rs948854 localized in the promoter region of the galanin gene is known to be 
associated with anxiety related disorders. It may also indicate increased vulnerability to opiate 
addiction since an increased number of homozygous carriers for the minor allele (G) was 
detected among opioid addicts (Beer et al., 2013).
4.7 Cannabinoid CB1- serotonin 5HT2a heteromers
THC binds to CB1 receptors which mediate both its beneficial effects such as analgesia, 
anxiolytic action and neuroprotection and detrimental effects such as dependence, anxiogenic 
action or memory impairment (Zou and Kumar, 2018). In addition, cannabis consumption in 
adolescents is well known to facilitate the appearance of psychosis involving the serotoninergic 
system (Karila et al., 2014). CB1 receptors are highly expressed in the rat striatum on 
presynaptic cortical inputs and postsynaptic dendrites of cells located in the patch and matrix 
compartments (Rodriguez et al., 2001). Since serotoninergic 5HT2a receptors are strongly 
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expressed in the PFC and are also present in the striatum (Pazos et al., 1985; Weber and 
Andrade, 2010), the existence of CB1-5HT2a heteromers has been postulated to underlie the 
functional interaction between the endocannabinoid and serotoninergic systems in this context.
CB1-5HT2a heteromers were identified in the cortex (somatomotor layers 1,2,3), 
hippocampus (CA3) and, dorsal striatum by in situ PLA in wild type mice but not in mice 
deficient for either receptor (Vinals et al., 2015). Infusion (i.c.v.) of the CB1 receptor 
transmembrane domains TM V or TM VI but not TM VII domain disrupted the PLA signal, 
indicating that physical association involve TM V and TMVI (Vinals et al., 2015). Importantly, 
no CB1-5HT2a heteromers could be detected in the Nacc (Vinals et al., 2015). 
In vivo disruption of the CB1-5HT2a physical contact as well as use of 5HT2a knock-out 
mice revealed that some THC effects such as hypolocomotion, hypothermia, analgesia, 
anxiogenic effect were exclusively mediated by the CB1 receptor (Vinals et al., 2015). In a 
protocol of self-administration, the reinforcing properties of the cannabinoid agonist 
WIN55,212-2 also remained unaffected in 5HT2a knock-out mice. This suggested no 
involvement of CB1-5HT2a heteromers in agreement with the absence of PLA signal in the 
Nacc (Vinals et al., 2015). However, following chronic THC administration, symptoms of 
withdrawal precipitated with the cannabinoid antagonist rimonabant were significantly 
attenuated in 5HT2a knock-out mice compared to wild type animals pointing to a possible 
involvement of the CB1-5HT2a heteromers in physical dependence (Vinals et al., 2015). In 
addition, memory impairment (novel object recognition task), anxiolytic effect (elevated plus 
maze) and increased social interaction induced by acute THC administration were reduced in 
5HT2a knock-out mice and/or upon disruption of the physical contact between the two receptors 
(Vinals et al., 2015). This indicates that CB1-5HT2a heteromers modulate these THC dependent 
effects, in particular, aspects of the THC associated cognitive deficits. 
22
At the cellular level, CB1-5HT2a heteromerization switched the 5HT2a receptor 
coupling from the Gq to the Gi pathway in co-transfected HEK293 cells (Vinals et al., 
2015). Co-activation of the receptors in co-transfected HEK293 cells reduced cell signaling by 
increasing cAMP inhibition and reducing -arrestin recruitment without altering ERK1/2 and 
Akt phosphorylation. (Vinals et al., 2015). Bidirectional cross-antagonism was also observed 
upon simultaneous administration of an antagonist for one receptor and an agonist for the other 
on cAMP production, -arrestin recruitment, ERK1/2 and Akt phosphorylation (Vinals et al., 
2015). Both negative crosstalk and cross-antagonism were reversed upon physical disruption 
of the CB1-5HT2a interaction in co-transfected HEK293 cells (Vinals et al., 2015). Importantly, 
both were observed in brain regions where CB1-5HT2a physical association was observed and 
were absent in 5HT2a knock-out mice (Vinals et al., 2015).
4.8 Cannabinoid CB1-adenosineA2a heteromers
Adenosine A2a and CB1 receptors are expressed in dendritic spines of striatopallidal 
GABAergic neurons and their close physical proximity was established by co-
immunoprecipitation from rat striatal membranes (Carriba et al., 2007; Ferreira et al., 2015). 
Further data in favor of heteromerization were collected in co-transfected cells by BRET 
experiments (Carriba et al., 2007). In SHSY5Y neuroblastoma that endogenously co-express 
the two receptors, efficient CB1 receptor coupling to inhibitory G protein requires simultaneous 
activation of A2a receptors and is abolished in the presence of an A2a selective antagonist 
indicative of cross-antagonism (Carriba et al., 2007). Accordingly, blocking A2a receptors with 
the A2a antagonist MSX-3 counteracted the decrease in locomotor activity promoted by 
intrastriatal bilateral administration of the CB1 agonist WIN55212-2 (Carriba et al., 2007). In 
addition, decreased conditioned place preference to THC was observed in A2a receptor knock-
out mice supporting a role for CB1-A2a heteromers (Soria et al., 2004). 
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Functional interaction of A2a and CB1 receptors in presynaptic corticostriatal synapses 
was also postulated using radioligand binding in nerve terminal membranes, glutamate release 
assay in acutely isolated nerve terminals and paired-pulse ratio measurements in isolated 
monosynaptic contacts in corticostriatal slices (Ferreira et al., 2015). However, in this case, A2a 
receptor activation dampened CB1 receptor function and CB1-mediated inhibition of 
corticostriatal glutamatergic inputs (Ferreira et al., 2015). These results suggest that activation 
of the A2a receptor would have opposite effects on CB1 receptor signaling depending on the 
pre- or post-synaptic localization of the CB1-A2a heteromer.
5. Class A-Class A Heteromers with potential role in SUD
Here, we review heteromers for which impact on cellular mechanisms relevant to SUD 
have been evidenced, although no direct behavioral outcome has been reported yet.
5.1 Mu opioid-cannabinoid CB1 heteromers
Both mu opioid and cannabinoid CB1 receptors are primary targets of drugs of abuse 
and widely expressed throughout the brain (Erbs et al., 2015; Nguyen et al., 2010).  
Heteromerization between these two receptors is thus bound to strongly alter drug effects. 
BRET measurements in co-transfected HEK293 cells established the ability of the two 
receptors to physically interact and ultrastructural analysis in the rat caudate putamen revealed 
discrete co-localization of the two receptors in MSNs (Rios et al., 2006). The presence of CB1 
receptors in mu enriched patches suggested that the two receptors could modulate the output 
of these GABAergic neurons (Rodriguez et al., 2001). This may account for the similar impact 
of the two receptors on motor activity. 
Interestingly, THC was reported to allosterically decrease opiate binding at the mu 
opioid receptor in rat brain membranes (Vaysse et al., 1987). In addition, simultaneous co-
activation of the receptors in SK-N-SH neuroblastoma cell line or rat striatal membranes 
decreased G protein-dependent signaling (Rios et al., 2006). This bidirectional negative 
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crosstalk was associated with decreased activation of the G protein-Src-STAT3 pathway in 
mu-transfected Neuro2a cells and a negative impact on neuritogenesis (Rios et al., 2006) which 
may contribute to drug related neuroplasticity. 
Social play has a strong rewarding value and is modulated by neurotransmitters 
involved in reward and motivation. Accordingly, increased activity of the opioid, 
endocannabinoid or dopamine receptors in the Nacc enhanced social play in rodents ((Manduca 
et al., 2016) and refs therein). Systemic injection of the endocannabinoid 2-arachidonoyl (2-
AG) hydrolysis inhibitor JZL184 increased social play behavior in adolescent rodents 
(Manduca et al., 2016). This effect was blocked by infusion in the NAcc of the mu antagonist 
CTAP and was absent in mu knock-out mice (Manduca et al., 2016). Reciprocally, systemic 
injection of the mu opioid agonist morphine increased social play and was abolished by the 
CB1 antagonist SR1417-16 or in CB1 knock-out mice (Manduca et al., 2016). Whole cell 
recordings of miniature excitatory postsynaptic currents revealed functional presynaptic 
interaction between CB1 and mu opioid receptors. Indeed, CB1 antagonists reduced the 
inhibition exerted by the mu opioid receptor on excitatory transmission influencing Nacc 
neurons and vice versa (Manduca et al., 2016). Altogether, these data revealed bidirectional 
cross-antagonism taking place at mu-CB1 heteromers and strongly suggest that functional mu-
CB1 heteromers in the Nacc can modulate the rewarding properties of drugs of abuse.
5.2 Cannabinoid CB1-CB2 heteromers
Cannabinoid CB1 receptors are the primary molecular target for THC. CB1 receptors 
are widely distributed throughout the brain (Nguyen et al., 2010). In the striatum, they are often 
located presynaptically on GABAergic terminals of interneurons or collaterals from MSNs 
(Matyas et al., 2006) but they are also present in glutamatergic terminals (Huang et al., 2001). 
Striatal postsynaptic CB1 receptors are located in the somatodendritic compartment of 
25
dynorphin and enkephalin positive MSNs (Callen et al., 2012; Martin et al., 2008) and 
references therein). CB2 receptors are mostly expressed outside the CNS but evidence is 
accumulating for their presence in the brain where they are mostly postsynaptic ((Callen et al., 
2012) and references therein). Physical proximity indicative of heteromer formation with the 
CB1 receptor was reported using in situ PLA in the rat striatum (Callen et al., 2012). 
As described for mu opioid-CB1 heteromers, CB1-CB2 co-activation resulted in a 
negative cross-talk on the Akt/PKB signaling and CB1-CB2 cross antagonism decreased 
ERK1/2 and Akt/PKB phosphorylation, thereby reducing neurite outgrowth (Callen et al., 
2012). Activation of the striatal microglia increased CB1-CB2 heteromerization. Moreover, 
microglial activation changed the negative crosstalk on CB1-CB2 signaling observed in resting 
cells upon co-stimulation by the CB1 agonist ACEA and the CB2 agonist JWH133 into a 
positive cross-talk in activated cells (Navarro et al., 2018a). This is in line with a study 
indicating that activation of the endocannabinoid system, and more specifically of the CB2 
receptor, before methamphetamine administration reduced the neurotoxicity of the drug (Nader 
et al., 2014).  Also, cocaine increased CB1 and decreased CB2 expression in the PFC and 
hippocampus of adolescent rats (Garcia-Cabrerizo and Garcia-Fuster, 2016). Although CB1-
CB2 heteromers have not been evidenced in the cortex so far, one can postulate that cocaine 
could prevent their neuroprotective effect by decreasing their expression, which may contribute 
to the addiction vulnerability observed in adolescents (Bagot et al., 2015). CB1-CB2 heteromers 
may therefore represent a therapeutic target to reduce neuroinflammation that develops in SUD 
(Karoly et al., 2015). 
5.3 Dopamine D3/D3nf  heteromers
Several pieces of evidence link the dopamine D3 receptor to SUD. First, expression of 
dopamine D3 receptors is increased in several brain areas from cocaine abusers, 
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metamphetamine users and alcohol dependent patients (for reviews (Prieto, 2017; Sokoloff and 
Le Foll, 2017). Second, the Ser9Gly polymorphism known to enhance ERK signaling and to 
be responsible for essential tremor has also been linked to early onset of heroin dependence in 
Han Chinese subjects (Kuo et al., 2014). Third, D3 receptors are involved in locomotor 
responses to spatial novelty and psychostimulants (Pritchard et al., 2006). Indeed, D3 receptors 
modulate glutamatergic pathways from the PFC to subcortical areas, either directly by 
interacting with N-methyl-D-aspartate (NMDA) receptors in the Nacc, or indirectly by 
controlling dopamine release from VTA neurons. Because D3 receptors are associated with the 
ventral forebrain mesolimbic system, they influence reward, emotions and motivation but also 
affects drug seeking and relapse, particularly related with  drug associated cues (for a recent 
review (Sokoloff and Le Foll, 2017).
Co-immunoprecipitation in rat brain revealed physical proximity between the D3 and 
truncated D3nf receptors (Nimchinsky et al., 1997). In baculovirus infected Sf9 cells, D3-D3nf 
heteromerization abolished D3 activity by inhibiting ligand binding to the receptor (Elmhurst 
et al., 2000). In co-transfected HEK 293 cells, D3-D3nf association led to predominant 
cytoplasmic mislocalization of the D3 receptor (Karpa et al., 2000). This inactive variant seems 
thus to play a regulatory role and to reduce functional D3 receptor availability. In the high 
responder/low responder model, individual differences in the locomotor responses to an 
inescapable, novel spatial environment predict individual differences in the locomotor and 
reinforcing effects of psychostimulants (Pritchard et al., 2006). In this model, the D3/D3nf ratio 
was decreased in the PFC, SN and VTA of rat high responder to novelty compared to low 
responder but remained unaffected in the Nacc (Pritchard et al., 2006). Accordingly, the 
D3/D3nf ratio has been proposed to play a role in cocaine sensitization and addiction (Richtand, 
2006). Surprisingly, in a protocol of sensitization to nicotine involving three exposures to the 
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drug, the D3/D3nf ratio was increased in the Nacc of adolescent and adult rats suggesting a 
potential increase in receptor D3 receptor availability (Smith et al., 2015). 
5.4 Dopamine D1-D3 heteromers
D1 and D3 receptors were co-immunoprecipitated from rat brain membranes (Fiorentini 
et al., 2008). Co-activation of the receptors potentiated the stimulatory effect of dopamine on 
cAMP and led to co-internalization of the two receptors in co-transfected HEK 293 cells 
(Fiorentini et al., 2008). Since agonist stimulation of D3 receptors did not promote D3 receptor 
internalization when expressed alone, this suggested a switch towards D1 receptor specific 
desensitization mechanisms (Fiorentini et al., 2008). In striatal membranes, enhanced agonist 
affinity was observed at the D1 receptor upon D3 receptor co-activation (Marcellino et al., 
2008). In reserpinized mice, a model to study the function of postsynaptic striatal dopamine 
receptors without the influence of endogenous dopamine, D3 receptor activation potentiated D1 
dependent locomotor activity (Marcellino et al., 2008). This positive cross-talk was 
counteracted by a D3 selective antagonist and abolished in D3 knock-out mice (Marcellino et 
al., 2008). D1-D3 heteromers by modulating the direct striatonigral pathway may therefore 
contribute to psychostimulant locomotor sensitization. 
5.5 Dopamine D1-histamine H3-sigma1 heteromers 
The histamine H3 receptor is abundantly expressed in the striatum and mostly located 
post-synaptically in both D1 and D2 expressing MSNs.  The interaction of the histamine H3 
receptor with the dopaminergic system and its implication in alcohol or psychostimulant abuse 
is well established (Bakker et al., 2006; Ellenbroek, 2013; Panula and Nuutinen, 2011). 
Physical proximity of histamine H3 and dopamine D1 receptors was verified by co-
immunoprecipitation experiments in rat (Moreno et al., 2011a) and mouse (Moreno et al., 
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2014) striatal membranes. It was further confirmed in the mouse striatum using PLA (Moreno 
et al., 2014). 
At the cellular level, the D1 receptor couples to the Gs subunit and increases cAMP 
production. However, in neuroblastoma cells co-transfected with D1 and H3 receptors, D1 
agonists led to reduced forskolin induced cAMP suggesting that the D1 receptor now activated 
the inhibitory Gi/o pathway through its association with the H3 receptor (Ferrada et al., 2009). 
Co-transfection of D1 and H3 receptors led to ERK1/2 phosphorylation upon activation by H3 
agonists which was not observed when the H3 receptor was expressed alone (Ferrada et al., 
2009). Accordingly, the ability of H3 receptors to stimulate ERK1/2 phosphorylation was not 
observed in D1 receptor knock-out mice (Moreno et al., 2011a) supporting a role for D1-H3 
heteromerization. Moreover, D1 receptor expression was decreased and no ERK1/2 
phosphorylation following D1 agonist activation was observed in the striatum of H3 receptor 
knock-out mice suggesting that the presence of the H3 receptor is required for the D1 receptor 
to be fully functional (Kononoff Vanhanen et al., 2016). However, H3 receptor activation 
inhibited D1 dependent ERK1/2 phosphorylation in striatal membrane revealing a negative 
crosstalk on D1 signaling when the two receptors were simultaneously activated (Moreno et 
al., 2014). 
Antagonists for either receptor blocked ERK1/2 phosphorylation in striatal membranes 
or neuroblastoma cells co-transfected with D1 and H3 receptors indicating that D1-H3 
heteromerization was also associated with bidirectional cross-antagonism (Ferrada et al., 2009; 
Moreno et al., 2014). 
Acute cocaine application on organotypic cultures from mouse striatum inhibited D1-
H3 bidirectional cross antagonism and reduced the negative cross-talk exerted by H3 receptor 
activation on D1 receptor signaling (Moreno et al., 2014). A similar impact on D1-H3 heteromer 
signaling was observed following chronic exposure to cocaine using striatal slices from rats 
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that self-administered the drug for 6-11 weeks (Moreno et al., 2014). Since none of the 
receptors has affinity for cocaine, association with the sigma1 receptor that efficiently binds 
this psychostimulant was postulated (Matsumoto et al., 2002). Co-immunoprecipitation and in 
situ PLA experiments both confirmed the physical proximity between sigma1 and D1 or H3 
receptors (Moreno et al., 2014). Accordingly, all tested effects of cocaine on D1-H3 heteromer 
signaling were abolished in striatal organotypic cultures from mice deficient for the sigma1 
receptor (Moreno et al., 2014). Since drugs of abuse all increase extracellular dopamine level 
which initiates oxidative stress and neurotoxicity (Cunha-Oliveira et al., 2008), the authors 
explored the functional role of D1-H3 heteromers on striatal neuron survival. Activation of D1 
receptors induced cell death that was counteracted by activation of the H3 receptor or by co-
administration of D1 or H3 selective antagonists (Moreno et al., 2014). Both effects were absent 
following exposure of the organotypic slices to cocaine (Moreno et al., 2014). Involvement of 
the sigma1 receptor in the cocaine effects on neuronal cell death was then investigated. 
Pretreatment with a sigma1 agonist mimicked cocaine effects whereas pretreatment with a 
sigma1 antagonist abolished blockade of both D1-H3 cross-antagonism and negative crosstalk 
on D1 signaling by cocaine (Moreno et al., 2014). Altogether, these data point to D1-H3-sigma1 
heterocomplexes as potential target for the treatment of cocaine abuse.
5.6 Dopamine D2-histamine H3 heteromers 
The histamine H3 receptor was co-immunoprecipitated with the dopamine D2 receptor 
in rat striatal membranes establishing physical proximity between them (Moreno et al., 2011a). 
In mice deficient for the H3 receptor, D2 agonist induced locomotion was altered and D2 
agonists did not promote ERK1/2 phosphorylation in the striatum (Kononoff Vanhanen et al., 
2016) supporting functional interaction in D2-H3 heteromers. 
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Since D2 receptors can also form heteromers with sigma1 (see section 4.2) or D1 (see 
section 4.3) receptors, larger complexes associating H3-D2-sigma1 receptors or H3-D2-D1-
sigma1 receptors may exist whose modulatory role of the striatal GABAergic signaling remains 
to be elucidated.
5.7 Adenosine A1-adenosine A2a heteromers
The Gi/o coupled adenosine A1 and Gs coupled A2a receptors co-localize in 
glutamatergic terminals in the rat striatum as indicated by co-immunoprecipitation and electron 
microscopy (Ciruela et al., 2006). Upon A1-A2a heteromerization, activation of the A2a receptor 
reduces the affinity and efficacy of A1 agonists consistent with a negative cross-talk on A1 
signaling (Ciruela et al., 2006).  A1 receptors have higher affinity for adenosine than A2A 
receptors. Accordingly, at low adenosine concentrations, preferred activation of A1 receptors 
will inhibit glutamate release whereas, at higher concentrations, adenosine will also bind to A2a 
receptors and facilitate glutamate release by inhibiting A1 signaling through A2a-A1 heteromers. 
Caffeine is a non-selective antagonist of A1 and A2a receptors with arousing and psychomotor 
effects similar to prototypical psychostimulants such as cocaine or amphetamines. Caffeine has 
higher affinity for A2a receptors than for A1 receptors in transfected cells expressing only one 
receptor type but A2a affinity for caffeine decreases upon A2a-A1 heteromerization (Ciruela et 
al., 2006). Acute caffeine that results in low adenosine concentration would block A1 receptors 
and enhance glutamatergic release. On the contrary, chronic caffeine would result in higher 
adenosine concentrations through inhibition of the ENT1 transporter and would inhibit 
glutamatergic release through A1-A2a heteromers (Ciruela et al., 2006). A1-A2a heteromers can 
therefore contribute to modulate striatal activity and may also associate with D2 and sigma1 
receptors to form larger heterocomplexes.
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5.8 Class A- class A heteromers with unexplored role in SUD
In vivo physical proximity has been reported for several additional class A receptor pairs 
involving at least one of the receptors playing a role in SUD. This includes cannabinoid CB1-
delta opioid receptors (cortex, striatum) (Bushlin et al., 2012), dopamine D2-somatostatin sst2 
receptors (primary striatal cultures) (Baragli et al., 2007), adenosine A2a-purinergic P2Y1 
receptors (cortex) (Yoshioka et al., 2002), mu opioid-adrenergic A2a receptors (primary 
hippocampal cultures, nucleus of the solitary tract) (Jordan et al., 2003; Sun et al., 2015), 
histamine H3 receptor- non-functional histamine H3 truncated splice variant (cortex, caudate 
putamen, hippocampus) (Bakker et al., 2006). The functional relevance of these heteromers in 
the context of SUD remains to be established but they could enrich the actual possibilities to 
modulate the various aspects of drug addiction. 
Also, additional heteromers have been described that do not involve receptors for drugs 
of abuse but modulate neuronal and/or glial functions such as those involving association of 
opioid and chemokine receptors (reviewed in (Melik Parsadaniantz et al., 2015) (Kramp et al., 
2011)) or heteromerization of serotonin receptors (reviewed in (Gaitonde and Gonzalez-
Maeso, 2017)). They are key players in neuroinflammation, nociception or depression, and 
may therefore contribute to the expression of symptoms associated with SUD. 
6. Class A-class C heteromers and SUD
Much less is known to date on the functional consequences of heteromerization between these 
class A and class C GPCRs in the context of drug addiction, However, the wide distribution of 
GABAB receptors (Charles et al., 2001), the presence of mGlu5 receptors in the cortex, striatum 
and Nacc and the high cortical expression of mGlu2 subunits (Ferraguti and Shigemoto, 2006) 
designate them as potential modulators of neuronal activity in the context of SUD and 
associated psychosis. 
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6.1 Serotonin 5HT2a-metabotropic glutamate mGlu2 heteromers
The implication of the serotoninergic system in mood, anxiodepressive disorders and 
other psychosis such as schizophrenia is well established. This neuromodulatory system is also 
the target of hallucinogenic substances isolated from mushrooms (psilocybin, mescaline) or of 
synthetic compounds such as LSD, which can also be abused leading to tolerance and 
psychological dependence (Das et al., 2016). These hallucinogenic drugs bind to 5HT2a 
receptors but not only recruit the canonical 5HT2a dependent Gq/11 pathway but also 
stimulate Gi/o signaling (Gonzalez-Maeso et al., 2008). Therefore, they modify the Gi/Gq 
coupling and signaling balance in favor of the inhibitory signaling cascade. 
Serotonin 5HT2a and metabotropic glutamate mGlu2 receptors were co-
immunoprecipitated in mouse (Fribourg et al., 2011) and human cortical membranes 
(Gonzalez-Maeso et al., 2008). The two receptors were also co-localized near synaptic 
junctions in mouse cortical neurons (Moreno et al., 2012). Studies using chimeras containing 
various ratios of mGlu2 receptor showed that the mGlu2 transmembrane domains TM IV and 
V are mandatory for association with 5HT2a receptors with three alanine residues (A677, A681, 
A685) at the TM IV intracellular end essential for heteromerization (Moreno et al., 2012).
In oocytes from Xenopus laevis co-expressing 5HT2a and mGlu2 receptors, 5HT2a 
mediated Gq/11 activation in response to serotonin was decreased by 50% and mGlu2 
mediated Gi/o signaling in response to glutamate was enhanced by 200%. Activation of 
5HT2a-mGlu2 heteromers by endogenous ligands therefore favored Gi over Gq signaling. 
This shift was specific to the 5HT2a-mGlu2 receptor pair since it was not observed upon co-
expression of the 5HT2a receptor with the non-interacting mGlu3 receptor (Fribourg et al., 
2011). In addition, occupancy of one of the receptors by an agonist, an antagonist or an inverse 
agonist differently affected Gq/Gi coupling. In oocytes co-expressing the two receptors, 
agonists favored signaling through their cognate receptor and decreased signaling though the 
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associated receptor indicative of bidirectional negative cross-talk. In contrast, positive 
allosteric modulation was observed with inverse agonists. Indeed, inverse agonists inhibited 
signaling through their cognate receptor and enhanced signaling through the associated 
receptor (Fribourg et al., 2011). Similar increases in signaling of the partner receptor by inverse 
agonist was also observed in cortical neurons in vivo (Fribourg et al., 2011). Accordingly, 
activation of the mGlu2 receptor by the agonist LY379268 suppressed the Gi dependent 
hallucinogenic effect of the 5HT2a agonist DOI in membranes from the mouse PFC (Gonzalez-
Maeso et al., 2008) and the effects of the inverse agonist LY341495 were significantly 
attenuated in 5HT2a knock-out mice (Fribourg et al., 2011; Gonzalez-Maeso et al., 2008). The 
causal link between 5HT2a-mGlu2 physical association and the head twitch behavioral response 
to hallucinogens was then conclusively established. In mice deficient for the mGlu2 receptor, 
administration of the 5HT2a agonist DOI did not induce head twitching revealing the essential 
role of this Gi coupled receptor (Moreno et al., 2011b). Rescuing mGlu2 receptor expression 
in the mouse frontal cortex upon herpes viral infection restored the behavioral response 
(Moreno et al., 2012). However, no behavioral response was observed following re-expression 
of a mGlu2 receptor missing the three alanine residues in the transmembrane domain TM IV 
that are essential for physical association with the 5HT2a (Moreno et al., 2012), confirming that 
5HT2a-mGlu2 heteromers mediate the specific response to hallucinogens.
6.2 Adenosine A2a- metabotropic glutamatergic mGlu5 heteromers
Physical proximity of adenosine A2a and metabotropic glutamate mGlu5 receptors was 
first determined by co-immunoprecipitation using rat striatal membranes (Ferre et al., 2002). 
Detection of A2a-mGlu5 heteromers by in situ PLA in mice revealed homogenous distribution 
throughout the striatum that was not affected in a protocol of habit formation (random interval 
training) or goal directed behavior (random ratio training) (He et al., 2016). The same approach 
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uncovered increased A2a-mGlu5 heteromers in the Nacc shell following cocaine self-
administration (Borroto-Escuela et al., 2017). Co-injection (i.c.v.) of the A2a agonist 
CGS21680 and the mGlu5 agonist CHPG led to increased c-Fos expression in the Nacc but not 
in the caudate putamen or in the cingulate cortex (Ferre et al., 2002). Dual-probe microdialysis 
in freely moving rats revealed that co-administration of the A2a agonist CGS21680 and the 
mGlu5 agonist CHPG led to synergistic effect and negatively modulated dopamine D2 signaling 
thereby enhancing glutamate and GABAergic extracellular levels in the globus pallidus 
(Beggiato et al., 2016). This suggests that A2a-mGlu5 heteromers may serve to overcome the 
strong tonic inhibitory effect of dopamine on striatal A2a function and may contribute to 
modulate locomotor activation and sensitization by psychostimulants. In addition, increased 
levels of heteromerization between A2a-D2, D2-sigma1, A2a-mGlu5 receptors detected by in situ 
PLA in the NAcc shell (Borroto-Escuela et al., 2017) suggest that these four receptors may 
associate in larger signaling platforms to modulate the striatopallidal activity.
6.3 Muscarinic M2-metabotropic GABAB2 heteromers
Co-expression of the GABAB2 but not the GABAB1 subunit in neuronal PC12 cells 
rescued surface expression of the muscarinic M2 receptor and functional coupling to GIRK 
channels upon chronic stimulation with acetylcholine (Boyer et al., 2009). Mutagenesis 
combined with FRET established that the interaction took place between the proximal C-
terminal domain of GABAB2 (P741 to V776) and the last 23 amino acids of the C–terminal 
domain of the muscarinic M2 receptor. Importantly, the interaction site on the GABAB2 
receptor was distinct from the coiled-coil domain responsible for the obligatory 
GABAB1/GABAB2 dimerization (Boyer et al., 2009). Therefore, it is unknown whether 
muscarinic M2 receptors interact with the GABAB2 receptor only or rather with the functional 
dimeric GABAB1/2 receptor. Co-immunoprecipitation from rat cortical membrane of GABAB2 
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subunit together with the muscarinic M2 receptor confirmed in vivo proximity (Boyer et al., 
2009) and suggested that the heteromer may play a role in drug addiction by modulating the 
endogenous acetylcholine tone at presynaptic level. A possible outcome would be a 
contribution of these heteromers to the discriminative stimulus properties of cocaine (Joseph 
and Thomsen, 2017).
7. Class A GPCR-ion channels heteromers with potential role in SUD
Physical association involving class A GPCRs is not restricted to interactions with 
another GPCR but can also involve ion channels, which would account for the growing 
complexity of interactions already identified. This emphasizes the need to adapt our current 
view of a functional unit to encompass broader associations taking place within a cluster of 
proteins of more than two types. 
7.1 Dopamine receptor- Voltage–gated Ca2+ channel heteromers
Physical proximity between dopamine D2 receptors and voltage gated N-type Ca2+ 
channels was identified by co-immunoprecipitation in the rat striatum (Kisilevsky and 
Zamponi, 2008) where the Gi/o coupled D2 receptors exert robust voltage dependent and 
independent inhibition of N-type channels. Importantly, voltage independent D2 inhibition 
appeared to be mediated through D2-N-type channel heteromerization since obliterated upon 
disruption of physical association. In addition, D2-N-type channel association increased cell 
surface expression of the channel and promoted D2 agonist-induced internalization in co-
transfected HEK 293 cells (Kisilevsky and Zamponi, 2008). 
Dopamine D1 receptors couple to Gs and enhance L-type Ca2+ channels through 
voltage independent pathways involving PKA activation. In the rat PFC, however, D1 receptors 
co-immunoprecipitated with N-type Ca2+ channels and inhibited their activity by a combination 
of voltage-dependent (G) and independent (PKA) pathways (Kisilevsky et al., 2008). In co-
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transfected HEK 293 cells, D1-N-type channel heteromer formation increased surface 
expression of the channel and promoted co-internalization following D1 activation (Kisilevsky 
et al., 2008). In primary cortical neurons, D1 receptors regulated channel distribution in 
dendritic compartments. Importantly, D1 regulation of N-type channel activity appeared 
selective to the PFC and was not observed in the striatum where no D1-channel physical 
proximity could be detected. The reason for this region specificity, however, remains unknown. 
Given the neuroplasticity induced by drugs of abuse that involve increased D1 signaling 
(Volkow and Morales, 2015), this type of interaction provides a mechanism by which D1 could 
contribute to dopaminergic inhibition of N-type channel activity during back propagating 
action potentials and hence could participate in the control exerted by the PFC on the striatum. 
The functional contribution of these heteromers in the context of SUD remains however to be 
established.
7.2 Opioid like receptor ORL1- Voltage–gated Ca2+ channel heteromers
Physical proximity between the Gi/o coupled opioid ORL1 receptor and the voltage 
gated N-type Ca2+ channels was established in the rat brain by co-immunoprecipitation (Beedle 
et al., 2004). Similar to the inhibitory control exerted by D1 or D2 receptors in the brain, N-type 
channel association with ORL1 resulted in a tonic inhibition of the channels in DRGs. The 
latter was attributed to ORL1 constitutive activity. The agonist nociceptin also led to G protein 
dependent inhibition of N-type channels and promoted receptor-channel co-internalization in 
the DRG, both mechanisms contributing to reduce Ca2+ entry (Altier et al., 2006). Regulation 
of N-type channel surface expression was also observed upon co-expression with D1 or D2 
dopamine receptors (Kisilevsky et al., 2008; Kisilevsky and Zamponi, 2008), and may reflect 
a general mechanism by which N-type channel expression and activity are regulated. ORL1 
and its endogenous ligand nociceptin/orphanin-FQ (N/OFQ) are widely distributed throughout 
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the brain and are present in areas that critically mediate motivated and addictive behaviors such 
as the central nucleus of the amygdala, the bed nucleus of the stria terminalis, the medial PFC, 
the VTA, or the Nacc (Ozawa et al., 2015). Activation of ORL1 regulates drug reward and 
drug-seeking behaviors associated with opiates, psychostimulants or ethanol (reviewed in 
(Witkin et al., 2014)). With respect to ethanol-mediated behaviors, ORL1 agonists attenuate 
conditioned place preference, ethanol self-administration, and ethanol-seeking behaviors in rat 
lines genetically-selected for high alcohol preference presumably through decreased dopamine 
release (reviewed in (Witkin et al., 2014)). In addition, mu opioid receptors can associate with 
ORL1 as shown by co-immunoprecipitation in the DRGs where activation of the mu opioid 
receptor led to co-internalization of the N-type channel. This was not observed when the ORL 
1 receptor was absent (Evans et al., 2010) and therefore indicates formation of larger 
heterocomplexes. Because of the broad overlap in the distributions of mu and ORL1 receptors 
(Ozawa et al., 2015) and the broad expression of N-type channels in the brain (Kamp et al., 
2012), such complexes are likely to form at supraspinal levels and may therefore participate to 
the response to drugs of abuse, especially when considering that the mu opioid receptor acts as 
a gateway for many of these (Contet et al., 2004). 
7.3 Class A receptor-NMDA channel heteromers
Co-immunoprecipitation experiments uncovered physical proximity between the 
dopamine D1 and the NR1 subunit of NMDA channels in the rat hippocampus (Pei et al., 2004) 
and striatal post-synaptic membrane preparations (Fiorentini et al., 2003). Interaction between 
the two proteins takes place in the ER and increases D1 receptor surface expression (Fiorentini 
et al., 2003) through contacts involving their C-termini (Pei et al., 2004). In addition, D1 
heteromerization with NR1 enhanced D1 signaling in primary hippocampal neurons (Pei et al., 
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2004) and abolished its internalization upon agonist activation in co-transfected HEK293 cells 
(Fiorentini et al., 2003)
Physical proximity was also identified by co-immunoprecipitation in the mouse 
periaqueductal gray between mu opioid receptors and the NR1 subunit of NMDA channels 
(Rodriguez-Munoz et al., 2012). Disruption of the complex by morphine contributed to the 
development of tolerance (Rodriguez-Munoz et al., 2012). Considering the ubiquitous 
distribution of the NR1 subunit, mu opioid-NMDA heteromers are likely to form in other brain 
regions. In addition, mu-D1 and D1-NMDA heteromers have been identified in the striatum 
suggesting the possibility of larger heterocomplexes that may represent a yet unrecognized 
modulator of neuronal activity contributing to SUD.
8. Heteromers as novel therapeutic targets
Vvery few novel pharmacological targets have proven effective in the clinic over the 
past three to four decades. Only minimal advances have been made, which emphasizes the need 
to address SUD treatment from a different perspective. Heteromerization as a mean for 
different GPCRs to alter behaviour by functioning together may therefore represents an 
alternative way to think about biological underpinnings of addiction. Indeed, heteromers have 
been detected in the human brain as for dopamine D1-D2 and 5HT2a-mGlu2 pairs (Gonzalez-
Maeso et al., 2008; Pei et al., 2010). In preclinical models, unambiguous implication in SUD 
has now been established for several receptor pairs. Although this identifies heteromers as 
novel therapeutic targets, the design of selective ligands is still in its infancy. 
Bivalent ligands have been developed to simultaneously bind two receptors in physical 
contact. Administration (i.c.v.) of the bivalent ligand MDAN-21 composed of the mu agonist 
oxymorphone and the delta antagonist naltrindole induced analgesia with low tolerance and 
low physical dependence (Daniels et al., 2005). This provided a proof of concept that the 
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strategy is of therapeutic interest. Selective targeting of mu-delta heteromers may indeed 
represent a valuable option, in particular for patients on opiate maintenance treatment. 
Integrated dual acting drugs combining heteromer selective targeting with a mixed 
agonist/ antagonist profile were also explored as a therapeutic approach. The strategy has been 
validated with eluxadoline, a mixed mu opioid agonist delta opioid antagonist recently 
approved by the FDA (Viberzi) for the treatment of irritable bowel syndrome. Arguments in 
favor of binding to mu-delta heteromers include lower efficacy in mice deficient for the delta 
opioid receptor and reduced signaling in the presence of mu-delta selective antibodies (Fujita 
et al., 2014). In the context of SUD, targeting A2a-D2 heteromers with a mixed A2a-antagonist-
D2 agonist (Jorg et al., 2015) may have therapeutic application by reducing habit formation 
developing upon chronic usage of psychostimulants. 
Attempts were also made to develop biased ligands with preferential affinity for 
heteromers. SKF83959 specifically targets D1-D2 heteromers and attenuates cocaine-induced 
locomotor sensitization and reinforcing properties as well as reinstatement of cocaine seeking 
(Hasbi et al., 2018). CYM51010, a monovalent ligand with preferential affinity for mu-delta 
heteromers, induced potent thermal analgesia comparable to morphine but lower tolerance and 
physical dependence (Gomes et al., 2013). Since CYM51010 showed no rewarding properties, 
this ligand is currently evaluated in preclinical models as an alternative to current opiate 
maintenance strategies such as methadone or buprenorphine (Massotte unpublished results). 
Finally, the concept of signalosome is also gaining importance in the context of SUD. 
Based on established physical proximity, complexes involving adenosine A2a, dopamine D2, 
sigma1 receptors and N-type channels, composed of histamine H3, dopamine D1, sigma1 
receptors and N-types channel or associating mu opioid, dopamine D1 and NMDA channels 
can now be reasonably postulated as plausible SUD-relevant functional units that fine-tune 
intracellular cascades. These large protein aggregates form signaling platforms and represent 
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an extended view of the current concept of heteromerization. Better characterization of these 
large functional ensembles should therefore pave the way to novel therapeutic options. 
Acknowledgements
We would like to thank Dr Cella Olmstead for fruitful discussions and critical reading 
of the manuscript.
41
References 
Altier, C., Khosravani, H., Evans, R.M., Hameed, S., Peloquin, J.B., Vartian, B.A., Chen, L., 
Beedle, A.M., Ferguson, S.S., Mezghrani, A., Dubel, S.J., Bourinet, E., McRory, J.E., 
Zamponi, G.W., 2006. ORL1 receptor-mediated internalization of N-type calcium 
channels. Nat Neurosci 9, 31-40.
Arolfo, M.P., Yao, L., Gordon, A.S., Diamond, I., Janak, P.H., 2004. Ethanol operant self-
administration in rats is regulated by adenosine A2 receptors. Alcohol Clin Exp Res 28, 
1308-1316.
Bagot, K.S., Milin, R., Kaminer, Y., 2015. Adolescent Initiation of Cannabis Use and Early-
Onset Psychosis. Subst Abus 36, 524-533.
Bakker, R.A., Lozada, A.F., van Marle, A., Shenton, F.C., Drutel, G., Karlstedt, K., Hoffmann, 
M., Lintunen, M., Yamamoto, Y., van Rijn, R.M., Chazot, P.L., Panula, P., Leurs, R., 
2006. Discovery of naturally occurring splice variants of the rat histamine H3 receptor 
that act as dominant-negative isoforms. Mol Pharmacol 69, 1194-1206.
Baragli, A., Alturaihi, H., Watt, H.L., Abdallah, A., Kumar, U., 2007. Heterooligomerization 
of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and 
fluorescence resonance energy transfer analysis. Cell Signal 19, 2304-2316.
Beedle, A.M., McRory, J.E., Poirot, O., Doering, C.J., Altier, C., Barrere, C., Hamid, J., 
Nargeot, J., Bourinet, E., Zamponi, G.W., 2004. Agonist-independent modulation of N-
type calcium channels by ORL1 receptors. Nat Neurosci 7, 118-125.
Beer, B., Erb, R., Pavlic, M., Ulmer, H., Giacomuzzi, S., Riemer, Y., Oberacher, H., 2013. 
Association of polymorphisms in pharmacogenetic candidate genes (OPRD1, GAL, 
ABCB1, OPRM1) with opioid dependence in European population: a case-control study. 
PLoS One 8, e75359.
42
Beggiato, S., Borelli, A.C., Borroto-Escuela, D., Corbucci, I., Tomasini, M.C., Marti, M., 
Antonelli, T., Tanganelli, S., Fuxe, K., Ferraro, L., 2017. Cocaine modulates allosteric 
D2-sigma1 receptor-receptor interactions on dopamine and glutamate nerve terminals 
from rat striatum. Cell Signal 40, 116-124.
Beggiato, S., Tomasini, M.C., Borelli, A.C., Borroto-Escuela, D.O., Fuxe, K., Antonelli, T., 
Tanganelli, S., Ferraro, L., 2016. Functional role of striatal A2A, D2, and mGlu5 receptor 
interactions in regulating striatopallidal GABA neuronal transmission. J Neurochem 138, 
254-264.
Bonaventura, J., Navarro, G., Casado-Anguera, V., Azdad, K., Rea, W., Moreno, E., 
Brugarolas, M., Mallol, J., Canela, E.I., Lluis, C., Cortes, A., Volkow, N.D., Schiffmann, 
S.N., Ferre, S., Casado, V., 2015. Allosteric interactions between agonists and 
antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer. 
Proc Natl Acad Sci U S A 112, E3609-3618.
Borroto-Escuela, D.O., Narvaez, M., Wydra, K., Pintsuk, J., Pinton, L., Jimenez-Beristain, A., 
Di Palma, M., Jastrzebska, J., Filip, M., Fuxe, K., 2017. Cocaine self-administration 
specifically increases A2AR-D2R and D2R-sigma1R heteroreceptor complexes in the rat 
nucleus accumbens shell. Relevance for cocaine use disorder. Pharmacol Biochem Behav 
155, 24-31.
Borroto-Escuela, D.O., Pintsuk, J., Schafer, T., Friedland, K., Ferraro, L., Tanganelli, S., Liu, 
F., Fuxe, K., 2016. Multiple D2 heteroreceptor complexes: new targets for treatment of 
schizophrenia. Ther Adv Psychopharmacol 6, 77-94.
Borroto-Escuela, D.O., Romero-Fernandez, W., Tarakanov, A.O., Gomez-Soler, M., Corrales, 
F., Marcellino, D., Narvaez, M., Frankowska, M., Flajolet, M., Heintz, N., Agnati, L.F., 
Ciruela, F., Fuxe, K., 2010. Characterization of the A2AR-D2R interface: focus on the 
43
role of the C-terminal tail and the transmembrane helices. Biochem Biophys Res 
Commun 402, 801-807.
Borroto-Escuela, D.O., Wydra, K., Li, X., Rodriguez, D., Carlsson, J., Jastrzebska, J., Filip, 
M., Fuxe, K., 2018. Disruption of A2AR-D2R Heteroreceptor Complexes After A2AR 
Transmembrane 5 Peptide Administration Enhances Cocaine Self-Administration in 
Rats. Mol Neurobiol.
Boyer, S.B., Clancy, S.M., Terunuma, M., Revilla-Sanchez, R., Thomas, S.M., Moss, S.J., 
Slesinger, P.A., 2009. Direct interaction of GABAB receptors with M2 muscarinic 
receptors enhances muscarinic signaling. J Neurosci 29, 15796-15809.
Bushlin, I., Gupta, A., Stockton, S.D., Jr., Miller, L.K., Devi, L.A., 2012. Dimerization with 
cannabinoid receptors allosterically modulates delta opioid receptor activity during 
neuropathic pain. PLoS One 7, e49789.
Callen, L., Moreno, E., Barroso-Chinea, P., Moreno-Delgado, D., Cortes, A., Mallol, J., 
Casado, V., Lanciego, J.L., Franco, R., Lluis, C., Canela, E.I., McCormick, P.J., 2012. 
Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J Biol Chem 
287, 20851-20865.
Capper-Loup, C., Canales, J.J., Kadaba, N., Graybiel, A.M., 2002. Concurrent activation of 
dopamine D1 and D2 receptors is required to evoke neural and behavioral phenotypes of 
cocaine sensitization. J Neurosci 22, 6218-6227.
Carriba, P., Ortiz, O., Patkar, K., Justinova, Z., Stroik, J., Themann, A., Muller, C., Woods, 
A.S., Hope, B.T., Ciruela, F., Casado, V., Canela, E.I., Lluis, C., Goldberg, S.R., 
Moratalla, R., Franco, R., Ferre, S., 2007. Striatal adenosine A2A and cannabinoid CB1 
receptors form functional heteromeric complexes that mediate the motor effects of 
cannabinoids. Neuropsychopharmacology 32, 2249-2259.
44
Charles, K.J., Evans, M.L., Robbins, M.J., Calver, A.R., Leslie, R.A., Pangalos, M.N., 2001. 
Comparative immunohistochemical localisation of GABA(B1a), GABA(B1b) and 
GABA(B2) subunits in rat brain, spinal cord and dorsal root ganglion. Neuroscience 106, 
447-467.
Ciruela, F., Burgueno, J., Casado, V., Canals, M., Marcellino, D., Goldberg, S.R., Bader, M., 
Fuxe, K., Agnati, L.F., Lluis, C., Franco, R., Ferre, S., Woods, A.S., 2004. Combining 
mass spectrometry and pull-down techniques for the study of receptor heteromerization. 
Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine 
D2 receptors. Anal Chem 76, 5354-5363.
Ciruela, F., Casado, V., Rodrigues, R.J., Lujan, R., Burgueno, J., Canals, M., Borycz, J., 
Rebola, N., Goldberg, S.R., Mallol, J., Cortes, A., Canela, E.I., Lopez-Gimenez, J.F., 
Milligan, G., Lluis, C., Cunha, R.A., Ferre, S., Franco, R., 2006. Presynaptic control of 
striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J 
Neurosci 26, 2080-2087.
Contet, C., Kieffer, B.L., Befort, K., 2004. Mu opioid receptor: a gateway to drug addiction. 
Curr Opin Neurobiol 14, 370-378.
Cunha-Oliveira, T., Rego, A.C., Oliveira, C.R., 2008. Cellular and molecular mechanisms 
involved in the neurotoxicity of opioid and psychostimulant drugs. Brain Res Rev 58, 
192-208.
Daniels, D.J., Lenard, N.R., Etienne, C.L., Law, P.Y., Roerig, S.C., Portoghese, P.S., 2005. 
Opioid-induced tolerance and dependence in mice is modulated by the distance between 
pharmacophores in a bivalent ligand series. Proc Natl Acad Sci U S A 102, 19208-19213.
Das, S., Barnwal, P., Ramasamy, A., Sen, S., Mondal, S., 2016. Lysergic acid diethylamide: a 
drug of 'use'? Ther Adv Psychopharmacol 6, 214-228.
45
Décaillot, F.M., Rozenfeld, R., Gupta, A., Devi, L.A., 2008. Cell surface targeting of mu-delta 
opioid receptor heterodimers by RTP4. Proc Natl Acad Sci U S A 105, 16045-16050.
Derouiche, L., Ory, S., Massotte, D., 2018. Double fluorescent knock-in mice to investigate 
endogenous mu-delta opioid heteromer subscellular distribution., in: Escuela, K.F.a.D.B. 
(Ed.), Receptor-Receptor Interactions in the Central Nervous System. Springer US.
Dunwiddie, T.V., Masino, S.A., 2001. The role and regulation of adenosine in the central 
nervous system. Annu Rev Neurosci 24, 31-55.
El Yacoubi, M., Ledent, C., Parmentier, M., Daoust, M., Costentin, J., Vaugeois, J., 2001. 
Absence of the adenosine A(2A) receptor or its chronic blockade decrease ethanol 
withdrawal-induced seizures in mice. Neuropharmacology 40, 424-432.
Ellenbroek, B.A., 2013. Histamine H(3) receptors, the complex interaction with dopamine and 
its implications for addiction. Br J Pharmacol 170, 46-57.
Elmhurst, J.L., Xie, Z., O'Dowd, B.F., George, S.R., 2000. The splice variant D3nf reduces 
ligand binding to the D3 dopamine receptor: evidence for heterooligomerization. Brain 
Res Mol Brain Res 80, 63-74.
Erbs, E., Faget, L., Scherrer, G., Matifas, A., Filliol, D., Vonesch, J.L., Koch, M., Kessler, P., 
Hentsch, D., Birling, M.C., Koutsourakis, M., Vasseur, L., Veinante, P., Kieffer, B.L., 
Massotte, D., 2015. A mu-delta opioid receptor brain atlas reveals neuronal co-
occurrence in subcortical networks. Brain Struct Funct 220, 677-702.
Evans, R.M., You, H., Hameed, S., Altier, C., Mezghrani, A., Bourinet, E., Zamponi, G.W., 
2010. Heterodimerization of ORL1 and opioid receptors and its consequences for N-type 
calcium channel regulation. J Biol Chem 285, 1032-1040.
Feltmann, K., Borroto-Escuela, D.O., Ruegg, J., Pinton, L., de Oliveira Sergio, T., Narvaez, 
M., Jimenez-Beristain, A., Ekstrom, T.J., Fuxe, K., Steensland, P., 2018. Effects of Long-
46
Term Alcohol Drinking on the Dopamine D2 Receptor: Gene Expression and 
Heteroreceptor Complexes in the Striatum in Rats. Alcohol Clin Exp Res 42, 338-351.
Fernandez-Duenas, V., Llorente, J., Gandia, J., Borroto-Escuela, D.O., Agnati, L.F., Tasca, 
C.I., Fuxe, K., Ciruela, F., 2012. Fluorescence resonance energy transfer-based 
technologies in the study of protein-protein interactions at the cell surface. Methods 57, 
467-472.
Fernandez-Duenas, V., Taura, J.J., Cottet, M., Gomez-Soler, M., Lopez-Cano, M., Ledent, C., 
Watanabe, M., Trinquet, E., Pin, J.P., Lujan, R., Durroux, T., Ciruela, F., 2015. 
Untangling dopamine-adenosine receptor-receptor assembly in experimental 
parkinsonism in rats. Dis Model Mech 8, 57-63.
Ferrada, C., Moreno, E., Casado, V., Bongers, G., Cortes, A., Mallol, J., Canela, E.I., Leurs, 
R., Ferre, S., Lluis, C., Franco, R., 2009. Marked changes in signal transduction upon 
heteromerization of dopamine D1 and histamine H3 receptors. Br J Pharmacol 157, 64-
75.
Ferraguti, F., Shigemoto, R., 2006. Metabotropic glutamate receptors. Cell Tissue Res 326, 
483-504.
Ferre, S., 2016. Mechanisms of the psychostimulant effects of caffeine: implications for 
substance use disorders. Psychopharmacology (Berl) 233, 1963-1979.
Ferre, S., Bonaventura, J., Zhu, W., Hatcher, C., Taura, J., Quiroz, C., Cai, N.S., Moreno, E., 
Casado-Anguera, V., Kravitz, A.V., Thompson, K.R., Tomasi, D., Navarro, G., Cordomi, 
A., Pardo, L., Lluis, C., Dessauer, C.W., Volkow, N.D., Casado, V., Ciruela, F., 
Logothetis, D.E., Zwilling, D., 2018. Essential Control of the Function of the 
Striatopallidal Neuron by Pre-coupled Complexes of Adenosine A2A-Dopamine D2 
Receptor Heterotetramers and Adenylyl Cyclase. Front Pharmacol 9, 243.
47
Ferre, S., Casado, V., Devi, L.A., Filizola, M., Jockers, R., Lohse, M.J., Milligan, G., Pin, J.P., 
Guitart, X., 2014. G protein-coupled receptor oligomerization revisited: functional and 
pharmacological perspectives. Pharmacol Rev 66, 413-434.
Ferre, S., Karcz-Kubicha, M., Hope, B.T., Popoli, P., Burgueno, J., Gutierrez, M.A., Casado, 
V., Fuxe, K., Goldberg, S.R., Lluis, C., Franco, R., Ciruela, F., 2002. Synergistic 
interaction between adenosine A2A and glutamate mGlu5 receptors: implications for 
striatal neuronal function. Proc Natl Acad Sci U S A 99, 11940-11945.
Ferreira, S.G., Goncalves, F.Q., Marques, J.M., Tome, A.R., Rodrigues, R.J., Nunes-Correia, 
I., Ledent, C., Harkany, T., Venance, L., Cunha, R.A., Kofalvi, A., 2015. Presynaptic 
adenosine A2A receptors dampen cannabinoid CB1 receptor-mediated inhibition of 
corticostriatal glutamatergic transmission. Br J Pharmacol 172, 1074-1086.
Fiorentini, C., Busi, C., Gorruso, E., Gotti, C., Spano, P., Missale, C., 2008. Reciprocal 
regulation of dopamine D1 and D3 receptor function and trafficking by 
heterodimerization. Mol Pharmacol 74, 59-69.
Fiorentini, C., Gardoni, F., Spano, P., Di Luca, M., Missale, C., 2003. Regulation of dopamine 
D1 receptor trafficking and desensitization by oligomerization with glutamate N-methyl-
D-aspartate receptors. J Biol Chem 278, 20196-20202.
Fredriksson, R., Schioth, H.B., 2005. The repertoire of G-protein-coupled receptors in fully 
sequenced genomes. Mol Pharmacol 67, 1414-1425.
Friberg, I.K., Young, A.B., Standaert, D.G., 1998. Differential localization of the mRNAs for 
the pertussis toxin insensitive G-protein alpha sub-units Gq, G11, and Gz in the rat brain, 
and regulation of their expression after striatal deafferentation. Brain Res Mol Brain Res 
54, 298-310.
Fribourg, M., Moreno, J.L., Holloway, T., Provasi, D., Baki, L., Mahajan, R., Park, G., Adney, 
S.K., Hatcher, C., Eltit, J.M., Ruta, J.D., Albizu, L., Li, Z., Umali, A., Shim, J., Fabiato, 
48
A., MacKerell, A.D., Jr., Brezina, V., Sealfon, S.C., Filizola, M., Gonzalez-Maeso, J., 
Logothetis, D.E., 2011. Decoding the signaling of a GPCR heteromeric complex reveals 
a unifying mechanism of action of antipsychotic drugs. Cell 147, 1011-1023.
Fujita, W., Gomes, I., Dove, L.S., Prohaska, D., McIntyre, G., Devi, L.A., 2014. Molecular 
characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor 
heteromers. Biochem Pharmacol 92, 448-456.
Furlong, T.M., Supit, A.S., Corbit, L.H., Killcross, S., Balleine, B.W., 2017. Pulling habits out 
of rats: adenosine 2A receptor antagonism in dorsomedial striatum rescues meth-
amphetamine-induced deficits in goal-directed action. Addict Biol 22, 172-183.
Fuxe, K., Marcellino, D., Leo, G., Agnati, L.F., 2010. Molecular integration via allosteric 
interactions in receptor heteromers. A working hypothesis. Curr Opin Pharmacol 10, 14-
22.
Gaitonde, S.A., Gonzalez-Maeso, J., 2017. Contribution of heteromerization to G protein-
coupled receptor function. Curr Opin Pharmacol 32, 23-31.
Garcia-Cabrerizo, R., Garcia-Fuster, M.J., 2016. Opposite regulation of cannabinoid CB1 and 
CB2 receptors in the prefrontal cortex of rats treated with cocaine during adolescence. 
Neurosci Lett 615, 60-65.
Gendron, L., Mittal, N., Beaudry, H., Walwyn, W., 2015. Recent advances on the delta opioid 
receptor: from trafficking to function. Br J Pharmacol 172, 403-419.
George, S.R., Fan, T., Xie, Z., Tse, R., Tam, V., Varghese, G., O'Dowd, B.F., 2000. 
Oligomerization of mu- and delta-opioid receptors. Generation of novel functional 
properties. Journal of Biological Chemistry 275, 26128-26135.
Golebiewska, U., Johnston, J.M., Devi, L., Filizola, M., Scarlata, S., 2011. Differential 
response to morphine of the oligomeric state of mu-opioid in the presence of delta-opioid 
receptors. Biochemistry 50, 2829-2837.
49
Gomes, I., Fujita, W., Gupta, A., Saldanha, S.A., Negri, A., Pinello, C.E., Eberhart, C., Roberts, 
E., Filizola, M., Hodder, P., Devi, L.A., 2013. Identification of a mu-delta opioid receptor 
heteromer-biased agonist with antinociceptive activity. Proc Natl Acad Sci U S A 110, 
12072-12077.
Gomes, I., Gupta, A., Filipovska, J., Szeto, H.H., Pintar, J.E., Devi, L.A., 2004. A role for 
heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. 
Proc Natl Acad Sci U S A 101, 5135-5139.
Gomes, I., Ijzerman, A.P., Ye, K., Maillet, E.L., Devi, L.A., 2011. G protein-coupled receptor 
heteromerization: a role in allosteric modulation of ligand binding. Mol Pharmacol 79, 
1044-1052.
Gomes, I., Jordan, B.A., Gupta, A., Trapaidze, N., Nagy, V., Devi, L.A., 2000. 
Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. Journal of 
Neuroscience 20, 1-5.
Gonzalez-Maeso, J., Ang, R.L., Yuen, T., Chan, P., Weisstaub, N.V., Lopez-Gimenez, J.F., 
Zhou, M., Okawa, Y., Callado, L.F., Milligan, G., Gingrich, J.A., Filizola, M., Meana, 
J.J., Sealfon, S.C., 2008. Identification of a serotonin/glutamate receptor complex 
implicated in psychosis. Nature 452, 93-97.
Gupta, A., Mulder, J., Gomes, I., Rozenfeld, R., Bushlin, I., Ong, E., Lim, M., Maillet, E., 
Junek, M., Cahill, C.M., Harkany, T., Devi, L.A., 2010. Increased abundance of opioid 
receptor heteromers after chronic morphine administration. Sci Signal 3, ra54.
Han, Y., Moreira, I.S., Urizar, E., Weinstein, H., Javitch, J.A., 2009. Allosteric communication 
between protomers of dopamine class A GPCR dimers modulates activation. Nat Chem 
Biol 5, 688-695.
50
Hasbi, A., Fan, T., Alijaniaram, M., Nguyen, T., Perreault, M.L., O'Dowd, B.F., George, S.R., 
2009. Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal 
BDNF production and neuronal growth. Proc Natl Acad Sci U S A 106, 21377-21382.
Hasbi, A., O'Dowd, B.F., George, S.R., 2011. Dopamine D1-D2 receptor heteromer signaling 
pathway in the brain: emerging physiological relevance. Mol Brain 4, 26.
Hasbi, A., Perreault, M.L., Shen, M.Y.F., Fan, T., Nguyen, T., Alijaniaram, M., Banasikowski, 
T.J., Grace, A.A., O'Dowd, B.F., Fletcher, P.J., George, S.R., 2018. Activation of 
Dopamine D1-D2 Receptor Complex Attenuates Cocaine Reward and Reinstatement of 
Cocaine-Seeking through Inhibition of DARPP-32, ERK, and DeltaFosB. Front 
Pharmacol 8, 924.
Hawes, J.J., Brunzell, D.H., Narasimhaiah, R., Langel, U., Wynick, D., Picciotto, M.R., 2008. 
Galanin protects against behavioral and neurochemical correlates of opiate reward. 
Neuropsychopharmacology 33, 1864-1873.
Hawes, J.J., Picciotto, M.R., 2004. Characterization of GalR1, GalR2, and GalR3 
immunoreactivity in catecholaminergic nuclei of the mouse brain. J Comp Neurol 479, 
410-423.
He, S.Q., Zhang, Z.N., Guan, J.S., Liu, H.R., Zhao, B., Wang, H.B., Li, Q., Yang, H., Luo, J., 
Li, Z.Y., Wang, Q., Lu, Y.J., Bao, L., Zhang, X., 2011. Facilitation of mu-opioid receptor 
activity by preventing delta-opioid receptor-mediated codegradation. Neuron 69, 120-
131.
He, Y., Li, Y., Chen, M., Pu, Z., Zhang, F., Chen, L., Ruan, Y., Pan, X., He, C., Chen, X., Li, 
Z., Chen, J.F., 2016. Habit Formation after Random Interval Training Is Associated with 
Increased Adenosine A2A Receptor and Dopamine D2 Receptor Heterodimers in the 
Striatum. Front Mol Neurosci 9, 151.
51
Hendry, I.A., Kelleher, K.L., Bartlett, S.E., Leck, K.J., Reynolds, A.J., Heydon, K., Mellick, 
A., Megirian, D., Matthaei, K.I., 2000. Hypertolerance to morphine in G(z alpha)-
deficient mice. Brain Res 870, 10-19.
Hillion, J., Canals, M., Torvinen, M., Casado, V., Scott, R., Terasmaa, A., Hansson, A., 
Watson, S., Olah, M.E., Mallol, J., Canela, E.I., Zoli, M., Agnati, L.F., Ibanez, C.F., 
Lluis, C., Franco, R., Ferre, S., Fuxe, K., 2002. Coaggregation, cointernalization, and 
codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 
277, 18091-18097.
Huang, C.C., Lo, S.W., Hsu, K.S., 2001. Presynaptic mechanisms underlying cannabinoid 
inhibition of excitatory synaptic transmission in rat striatal neurons. J Physiol 532, 731-
748.
Huang, L., Wu, D.D., Zhang, L., Feng, L.Y., 2013. Modulation of A(2)a receptor antagonist 
on D(2) receptor internalization and ERK phosphorylation. Acta Pharmacol Sin 34, 
1292-1300.
Jones, K.A., Borowsky, B., Tamm, J.A., Craig, D.A., Durkin, M.M., Dai, M., Yao, W.J., 
Johnson, M., Gunwaldsen, C., Huang, L.Y., Tang, C., Shen, Q., Salon, J.A., Morse, K., 
Laz, T., Smith, K.E., Nagarathnam, D., Noble, S.A., Branchek, T.A., Gerald, C., 1998. 
GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 
and GABA(B)R2. Nature 396, 674-679.
Jordan, B.A., Gomes, I., Rios, C., Filipovska, J., Devi, L.A., 2003. Functional interactions 
between mu opioid and alpha 2A-adrenergic receptors. Mol Pharmacol 64, 1317-1324.
Jorg, M., May, L.T., Mak, F.S., Lee, K.C., Miller, N.D., Scammells, P.J., Capuano, B., 2015. 
Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine 
A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease. J Med 
Chem 58, 718-738.
52
Joseph, L., Thomsen, M., 2017. Effects of muscarinic receptor antagonists on cocaine 
discrimination in wild-type mice and in muscarinic receptor M1, M2, and M4 receptor 
knockout mice. Behav Brain Res 329, 75-83.
Kabli, N., Fan, T., O'Dowd, B.F., George, S.R., 2014. mu-delta opioid receptor heteromer-
specific signaling in the striatum and hippocampus. Biochem Biophys Res Commun 450, 
906-911.
Kabli, N., Martin, N., Fan, T., Nguyen, T., Hasbi, A., Balboni, G., O'Dowd, B.F., George, S.R., 
2010. Agonists at the delta-opioid receptor modify the binding of micro-receptor agonists 
to the micro-delta receptor hetero-oligomer. Br J Pharmacol 161, 1122-1136.
Kabli, N., Nguyen, T., Balboni, G., O'Dowd, B.F., George, S.R., 2013. Antidepressant-like and 
anxiolytic-like effects following activation of the mu-delta opioid receptor heteromer in 
the nucleus accumbens. Mol Psychiatry.
Kamp, M.A., Hanggi, D., Steiger, H.J., Schneider, T., 2012. Diversity of presynaptic calcium 
channels displaying different synaptic properties. Rev Neurosci 23, 179-190.
Karila, L., Roux, P., Rolland, B., Benyamina, A., Reynaud, M., Aubin, H.J., Lancon, C., 2014. 
Acute and long-term effects of cannabis use: a review. Curr Pharm Des 20, 4112-4118.
Karoly, H.C., YorkWilliams, S.L., Hutchison, K.E., 2015. Clinical neuroscience of addiction: 
similarities and differences between alcohol and other drugs. Alcohol Clin Exp Res 39, 
2073-2084.
Karpa, K.D., Lin, R., Kabbani, N., Levenson, R., 2000. The dopamine D3 receptor interacts 
with itself and the truncated D3 splice variant d3nf: D3-D3nf interaction causes 
mislocalization of D3 receptors. Mol Pharmacol 58, 677-683.
Khelashvili, G., Dorff, K., Shan, J., Camacho-Artacho, M., Skrabanek, L., Vroling, B., 
Bouvier, M., Devi, L.A., George, S.R., Javitch, J.A., Lohse, M.J., Milligan, G., Neubig, 
R.R., Palczewski, K., Parmentier, M., Pin, J.P., Vriend, G., Campagne, F., Filizola, M., 
53
2010. GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base. 
Bioinformatics 26, 1804-1805.
Kisilevsky, A.E., Mulligan, S.J., Altier, C., Iftinca, M.C., Varela, D., Tai, C., Chen, L., 
Hameed, S., Hamid, J., Macvicar, B.A., Zamponi, G.W., 2008. D1 receptors physically 
interact with N-type calcium channels to regulate channel distribution and dendritic 
calcium entry. Neuron 58, 557-570.
Kisilevsky, A.E., Zamponi, G.W., 2008. D2 dopamine receptors interact directly with N-type 
calcium channels and regulate channel surface expression levels. Channels (Austin) 2, 
269-277.
Kononoff Vanhanen, J., Nuutinen, S., Tuominen, M., Panula, P., 2016. Histamine H3 Receptor 
Regulates Sensorimotor Gating and Dopaminergic Signaling in the Striatum. J 
Pharmacol Exp Ther 357, 264-272.
Koob, G.F., Volkow, N.D., 2010. Neurocircuitry of addiction. Neuropsychopharmacology 35, 
217-238.
Kramp, B.K., Sarabi, A., Koenen, R.R., Weber, C., 2011. Heterophilic chemokine receptor 
interactions in chemokine signaling and biology. Exp Cell Res 317, 655-663.
Kuo, S.C., Yeh, Y.W., Chen, C.Y., Huang, C.C., Chang, H.A., Yen, C.H., Ho, P.S., Liang, 
C.S., Chou, H.W., Lu, R.B., Huang, S.Y., 2014. DRD3 variation associates with early-
onset heroin dependence, but not specific personality traits. Prog Neuropsychopharmacol 
Biol Psychiatry 51, 1-8.
Lee, S.P., So, C.H., Rashid, A.J., Varghese, G., Cheng, R., Lanca, A.J., O'Dowd, B.F., George, 
S.R., 2004. Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase 
C-mediated calcium signal. J Biol Chem 279, 35671-35678.
Maggio, R., Rocchi, C., Scarselli, M., 2013. Experimental strategies for studying G protein-
coupled receptor homo- and heteromerization with radioligand binding and signal 
54
transduction methods, in: Conn, P.M. (Ed.), Methods in Enzymology: G protein coupled 
receptors trafficking and oligomerization. Elsevier Inc, pp. 295-310.
Manduca, A., Lassalle, O., Sepers, M., Campolongo, P., Cuomo, V., Marsicano, G., Kieffer, 
B., Vanderschuren, L.J., Trezza, V., Manzoni, O.J., 2016. Interacting Cannabinoid and 
Opioid Receptors in the Nucleus Accumbens Core Control Adolescent Social Play. Front 
Behav Neurosci 10, 211.
Marcellino, D., Ferre, S., Casado, V., Cortes, A., Le Foll, B., Mazzola, C., Drago, F., Saur, O., 
Stark, H., Soriano, A., Barnes, C., Goldberg, S.R., Lluis, C., Fuxe, K., Franco, R., 2008. 
Identification of dopamine D1-D3 receptor heteromers. Indications for a role of 
synergistic D1-D3 receptor interactions in the striatum. J Biol Chem 283, 26016-26025.
Marcellino, D., Navarro, G., Sahlholm, K., Nilsson, J., Agnati, L.F., Canela, E.I., Lluis, C., 
Arhem, P., Franco, R., Fuxe, K., 2010. Cocaine produces D2R-mediated conformational 
changes in the adenosine A(2A)R-dopamine D2R heteromer. Biochem Biophys Res 
Commun 394, 988-992.
Marcellino, D., Roberts, D.C., Navarro, G., Filip, M., Agnati, L., Lluis, C., Franco, R., Fuxe, 
K., 2007. Increase in A2A receptors in the nucleus accumbens after extended cocaine 
self-administration and its disappearance after cocaine withdrawal. Brain Res 1143, 208-
220.
Margolis, E.B., Fujita, W., Devi, L.A., Fields, H.L., 2017. Two delta opioid receptor subtypes 
are functional in single ventral tegmental area neurons, and can interact with the mu 
opioid receptor. Neuropharmacology 123, 420-432.
Martin, A.B., Fernandez-Espejo, E., Ferrer, B., Gorriti, M.A., Bilbao, A., Navarro, M., 
Rodriguez de Fonseca, F., Moratalla, R., 2008. Expression and function of CB1 receptor 
in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated 
motor behaviors. Neuropsychopharmacology 33, 1667-1679.
55
Matsumoto, R.R., McCracken, K.A., Pouw, B., Zhang, Y., Bowen, W.D., 2002. Involvement 
of sigma receptors in the behavioral effects of cocaine: evidence from novel ligands and 
antisense oligodeoxynucleotides. Neuropharmacology 42, 1043-1055.
Matyas, F., Yanovsky, Y., Mackie, K., Kelsch, W., Misgeld, U., Freund, T.F., 2006. 
Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. 
Neuroscience 137, 337-361.
Mei, J., Pasternak, G.W., 2001. Molecular cloning and pharmacological characterization of the 
rat sigma1 receptor. Biochem Pharmacol 62, 349-355.
Melik Parsadaniantz, S., Rivat, C., Rostene, W., Reaux-Le Goazigo, A., 2015. Opioid and 
chemokine receptor crosstalk: a promising target for pain therapy? Nat Rev Neurosci 16, 
69-78.
Moreno, E., Hoffmann, H., Gonzalez-Sepulveda, M., Navarro, G., Casado, V., Cortes, A., 
Mallol, J., Vignes, M., McCormick, P.J., Canela, E.I., Lluis, C., Moratalla, R., Ferre, S., 
Ortiz, J., Franco, R., 2011a. Dopamine D1-histamine H3 receptor heteromers provide a 
selective link to MAPK signaling in GABAergic neurons of the direct striatal pathway. 
J Biol Chem 286, 5846-5854.
Moreno, E., Moreno-Delgado, D., Navarro, G., Hoffmann, H.M., Fuentes, S., Rosell-Vilar, S., 
Gasperini, P., Rodriguez-Ruiz, M., Medrano, M., Mallol, J., Cortes, A., Casado, V., 
Lluis, C., Ferre, S., Ortiz, J., Canela, E., McCormick, P.J., 2014. Cocaine disrupts 
histamine H3 receptor modulation of dopamine D1 receptor signaling: sigma1-D1-H3 
receptor complexes as key targets for reducing cocaine's effects. J Neurosci 34, 3545-
3558.
Moreno, E., Quiroz, C., Rea, W., Cai, N.S., Mallol, J., Cortes, A., Lluis, C., Canela, E.I., 
Casado, V., Ferre, S., 2017. Functional mu-Opioid-Galanin Receptor Heteromers in the 
Ventral Tegmental Area. J Neurosci 37, 1176-1186.
56
Moreno, J.L., Holloway, T., Albizu, L., Sealfon, S.C., Gonzalez-Maeso, J., 2011b. 
Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and 
behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci Lett 
493, 76-79.
Moreno, J.L., Muguruza, C., Umali, A., Mortillo, S., Holloway, T., Pilar-Cuellar, F., Mocci, 
G., Seto, J., Callado, L.F., Neve, R.L., Milligan, G., Sealfon, S.C., Lopez-Gimenez, J.F., 
Meana, J.J., Benson, D.L., Gonzalez-Maeso, J., 2012. Identification of three residues 
essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A.mGlu2) 
receptor heteromerization and its psychoactive behavioral function. J Biol Chem 287, 
44301-44319.
Nader, J., Rapino, C., Gennequin, B., Chavant, F., Francheteau, M., Makriyannis, A., Duranti, 
A., Maccarrone, M., Solinas, M., Thiriet, N., 2014. Prior stimulation of the 
endocannabinoid system prevents methamphetamine-induced dopaminergic 
neurotoxicity in the striatum through activation of CB2 receptors. Neuropharmacology 
87, 214-221.
Nam, H.W., Hinton, D.J., Kang, N.Y., Kim, T., Lee, M.R., Oliveros, A., Adams, C., Ruby, 
C.L., Choi, D.S., 2013. Adenosine transporter ENT1 regulates the acquisition of goal-
directed behavior and ethanol drinking through A2A receptor in the dorsomedial 
striatum. J Neurosci 33, 4329-4338.
Navarro, G., Aguinaga, D., Moreno, E., Hradsky, J., Reddy, P.P., Cortes, A., Mallol, J., 
Casado, V., Mikhaylova, M., Kreutz, M.R., Lluis, C., Canela, E.I., McCormick, P.J., 
Ferre, S., 2014. Intracellular calcium levels determine differential modulation of 
allosteric interactions within G protein-coupled receptor heteromers. Chem Biol 21, 
1546-1556.
57
Navarro, G., Borroto-Escuela, D., Angelats, E., Etayo, I., Reyes-Resina, I., Pulido-Salgado, 
M., Rodriguez-Perez, A.I., Canela, E.I., Saura, J., Lanciego, J.L., Labandeira-Garcia, 
J.L., Saura, C.A., Fuxe, K., Franco, R., 2018a. Receptor-heteromer mediated regulation 
of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and 
relevance for Alzheimer's disease and levodopa-induced dyskinesia. Brain Behav Immun 
67, 139-151.
Navarro, G., Cordomi, A., Casado-Anguera, V., Moreno, E., Cai, N.S., Cortes, A., Canela, E.I., 
Dessauer, C.W., Casado, V., Pardo, L., Lluis, C., Ferre, S., 2018b. Evidence for 
functional pre-coupled complexes of receptor heteromers and adenylyl cyclase. Nat 
Commun 9, 1242.
Navarro, G., Moreno, E., Bonaventura, J., Brugarolas, M., Farre, D., Aguinaga, D., Mallol, J., 
Cortes, A., Casado, V., Lluis, C., Ferre, S., Franco, R., Canela, E., McCormick, P.J., 
2013. Cocaine inhibits dopamine D2 receptor signaling via sigma-1-D2 receptor 
heteromers. PLoS One 8, e61245.
Nelson, A.J., Killcross, S., 2013. Accelerated habit formation following amphetamine 
exposure is reversed by D1, but enhanced by D2, receptor antagonists. Front Neurosci 7, 
76.
Nguyen, E.C., McCracken, K.A., Liu, Y., Pouw, B., Matsumoto, R.R., 2005. Involvement of 
sigma (sigma) receptors in the acute actions of methamphetamine: receptor binding and 
behavioral studies. Neuropharmacology 49, 638-645.
Nguyen, P.T., Selley, D.E., Sim-Selley, L.J., 2010. Statistical Parametric Mapping reveals 
ligand and region-specific activation of G-proteins by CB1 receptors and non-CB1 sites 
in the 3D reconstructed mouse brain. Neuroimage 52, 1243-1251.
58
Nimchinsky, E.A., Hof, P.R., Janssen, W.G., Morrison, J.H., Schmauss, C., 1997. Expression 
of dopamine D3 receptor dimers and tetramers in brain and in transfected cells. J Biol 
Chem 272, 29229-29237.
Noori, H.R., Cosa Linan, A., Spanagel, R., 2016. Largely overlapping neuronal substrates of 
reactivity to drug, gambling, food and sexual cues: A comprehensive meta-analysis. Eur 
Neuropsychopharmacol 26, 1419-1430.
O'Dowd, B.F., Ji, X., Nguyen, T., George, S.R., 2012. Two amino acids in each of D1 and D2 
dopamine receptor cytoplasmic regions are involved in D1-D2 heteromer formation. 
Biochem Biophys Res Commun 417, 23-28.
O'Neill, C.E., LeTendre, M.L., Bachtell, R.K., 2012. Adenosine A2A receptors in the nucleus 
accumbens bi-directionally alter cocaine seeking in rats. Neuropsychopharmacology 37, 
1245-1256.
Ozawa, A., Brunori, G., Mercatelli, D., Wu, J., Cippitelli, A., Zou, B., Xie, X.S., Williams, M., 
Zaveri, N.T., Low, S., Scherrer, G., Kieffer, B.L., Toll, L., 2015. Knock-In Mice with 
NOP-eGFP Receptors Identify Receptor Cellular and Regional Localization. J Neurosci 
35, 11682-11693.
Panula, P., Nuutinen, S., 2011. Histamine and H3 receptor in alcohol-related behaviors. J 
Pharmacol Exp Ther 336, 9-16.
Pazos, A., Cortes, R., Palacios, J.M., 1985. Quantitative autoradiographic mapping of serotonin 
receptors in the rat brain. II. Serotonin-2 receptors. Brain Res 346, 231-249.
Pei, L., Lee, F.J., Moszczynska, A., Vukusic, B., Liu, F., 2004. Regulation of dopamine D1 
receptor function by physical interaction with the NMDA receptors. J Neurosci 24, 1149-
1158.
59
Pei, L., Li, S., Wang, M., Diwan, M., Anisman, H., Fletcher, P.J., Nobrega, J.N., Liu, F., 2010. 
Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects. 
Nat Med 16, 1393-1395.
Pellissier, L.P., Barthet, G., Gaven, F., Cassier, E., Trinquet, E., Pin, J.P., Marin, P., Dumuis, 
A., Bockaert, J., Baneres, J.L., Claeysen, S., 2011. G protein activation by serotonin type 
4 receptor dimers: evidence that turning on two protomers is more efficient. J Biol Chem 
286, 9985-9997.
Perreault, M.L., Fan, T., Alijaniaram, M., O'Dowd, B.F., George, S.R., 2012a. Dopamine D1-
D2 receptor heteromer in dual phenotype GABA/glutamate-coexpressing striatal 
medium spiny neurons: regulation of BDNF, GAD67 and VGLUT1/2. PLoS One 7, 
e33348.
Perreault, M.L., Hasbi, A., Alijaniaram, M., Fan, T., Varghese, G., Fletcher, P.J., Seeman, P., 
O'Dowd, B.F., George, S.R., 2010. The dopamine D1-D2 receptor heteromer localizes 
in dynorphin/enkephalin neurons: increased high affinity state following amphetamine 
and in schizophrenia. J Biol Chem 285, 36625-36634.
Perreault, M.L., Hasbi, A., Alijaniaram, M., O'Dowd, B.F., George, S.R., 2012b. Reduced 
striatal dopamine D1-D2 receptor heteromer expression and behavioural subsensitivity 
in juvenile rats. Neuroscience 225, 130-139.
Perreault, M.L., Hasbi, A., Shen, M.Y.F., Fan, T., Navarro, G., Fletcher, P.J., Franco, R., 
Lanciego, J.L., George, S.R., 2016. Disruption of a dopamine receptor complex amplifies 
the actions of cocaine. Eur Neuropsychopharmacol 26, 1366-1377.
Pierce, R.C., Quick, E.A., Reeder, D.C., Morgan, Z.R., Kalivas, P.W., 1998. Calcium-mediated 
second messengers modulate the expression of behavioral sensitization to cocaine. J 
Pharmacol Exp Ther 286, 1171-1176.
60
Pin, J.P., Neubig, R., Bouvier, M., Devi, L., Filizola, M., Javitch, J.A., Lohse, M.J., Milligan, 
G., Palczewski, K., Parmentier, M., Spedding, M., 2007. International Union of Basic 
and Clinical Pharmacology. LXVII. Recommendations for the recognition and 
nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev 59, 5-13.
Prieto, G.A., 2017. Abnormalities of Dopamine D3 Receptor Signaling in the Diseased Brain. 
J Cent Nerv Syst Dis 9, 1179573517726335.
Pritchard, L.M., Logue, A.D., Taylor, B.C., Ahlbrand, R., Welge, J.A., Tang, Y., Sharp, F.R., 
Richtand, N.M., 2006. Relative expression of D3 dopamine receptor and alternative 
splice variant D3nf mRNA in high and low responders to novelty. Brain Res Bull 70, 
296-303.
Rashid, A.J., So, C.H., Kong, M.M., Furtak, T., El-Ghundi, M., Cheng, R., O'Dowd, B.F., 
George, S.R., 2007. D1-D2 dopamine receptor heterooligomers with unique 
pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc Natl Acad 
Sci U S A 104, 654-659.
Richtand, N.M., 2006. Behavioral sensitization, alternative splicing, and d3 dopamine 
receptor-mediated inhibitory function. Neuropsychopharmacology 31, 2368-2375.
Rico, A.J., Dopeso-Reyes, I.G., Martinez-Pinilla, E., Sucunza, D., Pignataro, D., Roda, E., 
Marin-Ramos, D., Labandeira-Garcia, J.L., George, S.R., Franco, R., Lanciego, J.L., 
2017. Neurochemical evidence supporting dopamine D1-D2 receptor heteromers in the 
striatum of the long-tailed macaque: changes following dopaminergic manipulation. 
Brain Struct Funct 222, 1767-1784.
Rios, C., Gomes, I., Devi, L.A., 2006. mu opioid and CB1 cannabinoid receptor interactions: 
reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 148, 387-
395.
61
Rodriguez, J.J., Mackie, K., Pickel, V.M., 2001. Ultrastructural localization of the CB1 
cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. 
J Neurosci 21, 823-833.
Rodriguez-Munoz, M., Sanchez-Blazquez, P., Vicente-Sanchez, A., Berrocoso, E., Garzon, J., 
2012. The mu-opioid receptor and the NMDA receptor associate in PAG neurons: 
implications in pain control. Neuropsychopharmacology 37, 338-349.
Rondard, P., Goudet, C., Kniazeff, J., Pin, J.P., Prezeau, L., 2011. The complexity of their 
activation mechanism opens new possibilities for the modulation of mGlu and GABAB 
class C G protein-coupled receptors. Neuropharmacology 60, 82-92.
Rozenfeld, R., Devi, L.A., 2007. Receptor heterodimerization leads to a switch in signaling: 
beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers. Faseb 
J 21, 2455-2465.
Salim, K., Fenton, T., Bacha, J., Urien-Rodriguez, H., Bonnert, T., Skynner, H.A., Watts, E., 
Kerby, J., Heald, A., Beer, M., McAllister, G., Guest, P.C., 2002. Oligomerization of G-
protein-coupled receptors shown by selective co-immunoprecipitation. J Biol Chem 277, 
15482-15485.
Sambo, D.O., Lebowitz, J.J., Khoshbouei, H., 2018. The sigma-1 receptor as a regulator of 
dopamine neurotransmission: A potential therapeutic target for methamphetamine 
addiction. Pharmacol Ther.
Sanchez-Blazquez, P., Gomez-Serranillos, P., Garzon, J., 2001. Agonists determine the pattern 
of G-protein activation in m-opioid receptor-mediated supraspinal analgesia. Brain 
Research Bulletin 54, 229-235.
Schmidt, H.R., Zheng, S., Gurpinar, E., Koehl, A., Manglik, A., Kruse, A.C., 2016. Crystal 
structure of the human sigma1 receptor. Nature 532, 527-530.
62
Smith, L.N., Bachus, S.E., McDonald, C.G., Smith, R.F., 2015. Role of the D3 dopamine 
receptor in nicotine sensitization. Behav Brain Res 289, 92-104.
Sokoloff, P., Le Foll, B., 2017. The dopamine D3 receptor, a quarter century later. Eur J 
Neurosci 45, 2-19.
Soria, G., Castane, A., Berrendero, F., Ledent, C., Parmentier, M., Maldonado, R., Valverde, 
O., 2004. Adenosine A2A receptors are involved in physical dependence and place 
conditioning induced by THC. Eur J Neurosci 20, 2203-2213.
Soriano, A., Ventura, R., Molero, A., Hoen, R., Casado, V., Cortes, A., Fanelli, F., Albericio, 
F., Lluis, C., Franco, R., Royo, M., 2009. Adenosine A2A receptor-antagonist/dopamine 
D2 receptor-agonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor 
heteromers. J Med Chem 52, 5590-5602.
Spear, L.P., 2016. Consequences of adolescent use of alcohol and other drugs: Studies using 
rodent models. Neurosci Biobehav Rev 70, 228-243.
Sun, G.C., Ho, W.Y., Chen, B.R., Cheng, P.W., Cheng, W.H., Hsu, M.C., Yeh, T.C., Hsiao, 
M., Lu, P.J., Tseng, C.J., 2015. GPCR dimerization in brainstem nuclei contributes to the 
development of hypertension. Br J Pharmacol 172, 2507-2518.
Tao, Y.M., Yu, C., Wang, W.S., Hou, Y.Y., Xu, X.J., Chi, Z.Q., Ding, Y.Q., Wang, Y.J., Liu, 
J.G., 2017. Heteromers of mu opioid and dopamine D1 receptors modulate opioid-
induced locomotor sensitization in a dopamine-independent manner. Br J Pharmacol 174, 
2842-2861.
Taura, J., Valle-Leon, M., Sahlholm, K., Watanabe, M., Van Craenenbroeck, K., Fernandez-
Duenas, V., Ferre, S., Ciruela, F., 2017. Behavioral control by striatal adenosine A2A -
dopamine D2 receptor heteromers. Genes Brain Behav.
Tepper, J.M., Abercrombie, E.D., Bolam, J.P., 2007. Basal ganglia macrocircuits. Prog Brain 
Res 160, 3-7.
63
Torvinen, M., Kozell, L.B., Neve, K.A., Agnati, L.F., Fuxe, K., 2004. Biochemical 
identification of the dopamine D2 receptor domains interacting with the adenosine A2A 
receptor. J Mol Neurosci 24, 173-180.
Trifilieff, P., Rives, M.L., Urizar, E., Piskorowski, R.A., Vishwasrao, H.D., Castrillon, J., 
Schmauss, C., Slattman, M., Gullberg, M., Javitch, J.A., 2011. Detection of antigen 
interactions ex vivo by proximity ligation assay: endogenous dopamine D2-adenosine 
A2A receptor complexes in the striatum. Biotechniques 51, 111-118.
Tsvetanova, N.G., Irannejad, R., von Zastrow, M., 2015. G protein-coupled receptor (GPCR) 
signaling via heterotrimeric G proteins from endosomes. J Biol Chem 290, 6689-6696.
van Rijn, R.M., Brissett, D.I., Whistler, J.L., 2012. Emergence of functional spinal delta opioid 
receptors after chronic ethanol exposure. Biol Psychiatry 71, 232-238.
van Rijn, R.M., Whistler, J.L., 2009. The delta(1) opioid receptor is a heterodimer that opposes 
the actions of the delta(2) receptor on alcohol intake. Biol Psychiatry 66, 777-784.
Vaysse, P.J., Gardner, E.L., Zukin, R.S., 1987. Modulation of rat brain opioid receptors by 
cannabinoids. J Pharmacol Exp Ther 241, 534-539.
Verma, V., Hasbi, A., O'Dowd, B.F., George, S.R., 2010. Dopamine D1-D2 receptor 
Heteromer-mediated calcium release is desensitized by D1 receptor occupancy with or 
without signal activation: dual functional regulation by G protein-coupled receptor 
kinase 2. J Biol Chem 285, 35092-35103.
Vinals, X., Moreno, E., Lanfumey, L., Cordomi, A., Pastor, A., de La Torre, R., Gasperini, P., 
Navarro, G., Howell, L.A., Pardo, L., Lluis, C., Canela, E.I., McCormick, P.J., 
Maldonado, R., Robledo, P., 2015. Cognitive Impairment Induced by Delta9-
tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and 
Serotonin 5-HT2A Receptors. PLoS Biol 13, e1002194.
64
Vischer, H.F., Castro, M., Pin, J.P., 2015. G Protein-Coupled Receptor Multimers: A Question 
Still Open Despite the Use of Novel Approaches. Mol Pharmacol 88, 561-571.
Volkow, N.D., Morales, M., 2015. The Brain on Drugs: From Reward to Addiction. Cell 162, 
712-725.
Weber, E.T., Andrade, R., 2010. Htr2a Gene and 5-HT(2A) Receptor Expression in the 
Cerebral Cortex Studied Using Genetically Modified Mice. Front Neurosci 4.
Witkin, J.M., Statnick, M.A., Rorick-Kehn, L.M., Pintar, J.E., Ansonoff, M., Chen, Y., Tucker, 
R.C., Ciccocioppo, R., 2014. The biology of Nociceptin/Orphanin FQ (N/OFQ) related 
to obesity, stress, anxiety, mood, and drug dependence. Pharmacol Ther 141, 283-299.
Xie, W.Y., He, Y., Yang, Y.R., Li, Y.F., Kang, K., Xing, B.M., Wang, Y., 2009. Disruption of 
Cdk5-associated phosphorylation of residue threonine-161 of the delta-opioid receptor: 
impaired receptor function and attenuated morphine antinociceptive tolerance. J 
Neurosci 29, 3551-3564.
Yoshioka, K., Saitoh, O., Nakata, H., 2002. Agonist-promoted heteromeric oligomerization 
between adenosine A(1) and P2Y(1) receptors in living cells. FEBS Lett 523, 147-151.
Zou, S., Kumar, U., 2018. Cannabinoid Receptors and the Endocannabinoid System: Signaling 
and Function in the Central Nervous System. Int J Mol Sci 19.
65
Figure legends
Figure 1: The mesocorticolimbic pathway in rodents. 
The mesocorticolimbic pathway is involved in the reinforcing properties of drugs of abuse. 
Dopaminergic projections (DA) originating from the ventral tegmental area (VTA) are shown. 
Nacc, nucleus accumbens ; SN, substantia nigra; CeA, central amygdala; BNST, bed nucleus 
of the stria terminalis; LH, lateral hypothalamus.
Figure 2: Heteromers modulate dopamine transmission
(A) Native heteromers can modulate the direct striato-nigral pathway expressing the dopamine 
D1 receptor and the indirect striato-pallidal pathway expressing the dopamine D2 receptor. A 
third striatal output is composed of a discrete neuronal population of the ventral striatum 
expressing D1-D2 heteromers. Cross-talks within the heteromers and impact on neuronal 
activity are indicated.  MSN, medium spiny neuron; Glu, glutamate.
(B) Neuroanatomical distribution of native heteromers that can modulate the 
mesocorticolimbic pathway and contribute to substance use disorder.
Figure 3: Altered expression of heteromers in the context of substance use disorder.
Expression of heteromers is dynamic and affected by the physiological state and/or by drugs 
of abuse. Changes in heteromer expression identified in the mesocorticolimbic pathway by 
proximity ligation assay or selective antibodies are indicated. 
Figure 4: Proposed model for adenosine A2a receptor and dopamine D2 receptor 
interactions in A2a-D2 heterotetramers.
The association of two A2a-D2 heteromers generates a heterotetramer in which multiple 
interactions can simultaneously take place in the presence of ligands. Activation of the 
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adenosine A2a receptor by adenosine or an exogenous agonist negatively modulates D2 agonist 
affinity and efficacy through physical interactions within the A2a-D2 heteromer. This allosteric 
modulation therefore dampens dopamine D2 receptor G-protein-dependent and independent 
signaling. Reciprocally, activation of the dopamine D2 receptor by dopamine or an exogenous 
agonist can negatively cross-modulate A2a receptor affinity and signaling. Additional cross-
talks take place at the level of the signaling cascades. They correspond to canonical interactions 
between stimulatory Gs dependent and inhibitory Gi/o dependent pathways. They modulate 
cAMP production in opposite directions. The heterotetrameric organization enables additional 
modulations by A2a antagonists such as caffeine that would decrease the negative crosstalk on 
D2 receptor and reduce Gs dependent signaling (adapted from (Taura et al., 2017) (Navarro 
et al., 2018b) .
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Table 1
Heteromers with identified and potential implication in SUD
Abbreviations: Co-IP: co-immunoprecipitation, FRET: fluorescence resonance energy transfer, nd: not determined, PLA: proximity ligation assay
Heteromer In vivo physical proximity Impact on signaling 
properties
Postulated role in SUD References
Tissue Techniques
Class A-Class A heteromers with established role in SUD
A2a-D2 Rat and 
mouse 
striatum
Expression 
modulated by 
cocaine, 
ethanol or 
habit 
formation
Co-IP
PLA
Bivalent ligands
Electron microscopy
Time resolved-
FRET
Disruptive peptide
Bidirectional negative cross-
talk
Co-internalization
Habit formation 
Drug relapse (cocaine reinstatement)
↑ Ethanol consumption 
↓ Ethanol withdrawal
Caffeine stimulatory effect
(Borroto-Escuela et al., 2017; 
Borroto-Escuela et al., 2018; 
El Yacoubi et al., 2001; 
Feltmann et al., 2018; 
Fernandez-Duenas et al., 
2015; He et al., 2016; Hillion 
et al., 2002; Huang et al., 
2013; Marcellino et al., 2007; 
Soriano et al., 2009; Trifilieff 
et al., 2011)
D2-sigma1 Rat and 
mouse 
striatum
Expression 
modulated by 
cocaine or 
ethanol
Co-IP
PLA
Negative cross-talk on D2 
signaling 
Binds and mediates cocaine negative 
cross-talk on D2 signaling
(Beggiato et al., 2017; 
Borroto-Escuela et al., 2017; 
Feltmann et al., 2018; Navarro 
et al., 2013)
D1-D2 Rat, mouse, 
long-tail 
macaque, 
human 
striatum
Co-IP
FRET
Gq/11 signaling (BDNF 
pathway)
↑BDNF
↓Cocaine locomotor sensitization
↓ Cocaine reinforcing properties (CPP)
(Hasbi et al., 2009; Hasbi et 
al., 2018; Lee et al., 2004; Pei 
et al., 2010; Perreault et al., 
2016; Rashid et al., 2007; 
Rico et al., 2017)
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Expression 
increased 
with age
PLA
Disruptive peptide
↓Cocaine self-administration
↓Cocaine seeking (reinstatement of self-
administration by drug or cue priming)
↓Susceptibility to cocaine in adulthood
↓Sucrose preference
↓motivation (palatable food)
Drug induced neuroplasticity
Mu-D1 Mouse 
striatum
Co-IP Cross-antagonism on mu 
signaling
Locomotor sensitization to opiates (Tao et al., 2017)
Mu-delta Mouse 
hippocampus, 
VTA
Expression 
modulated by 
chronic 
morphine
Co-IP
Heteromer specific 
antibody
Bivalent ligand
Disruptive peptide 
Bidirectional positive cross-talk 
on ligand binding and signaling
Gz coupling
Co-internalization 
↑ -arrestin signaling
↓tolerance
↓physical dependence
↓ethanol consumption
(Daniels et al., 2005; 
Derouiche et al., 2018; Erbs et 
al., 2015; George et al., 2000; 
Gomes et al., 2013; Gomes et 
al., 2004; Gomes et al., 2011; 
Gomes et al., 2000; Gupta et 
al., 2010; He et al., 2011; 
Kabli et al., 2010; Kabli et al., 
2013; Margolis et al., 2017; 
Rozenfeld and Devi, 2007; 
van Rijn and Whistler, 2009)
Mu-Gal1 Mouse VTA Disruptive peptide Cross-antagonism on Gal1 
signaling 
Negative cross-talk on mu 
signaling  
↓Opiates reinforcement and withdrawal (Hawes et al., 2008; Moreno 
et al., 2017)
CB1-5HT2a Mouse cortex, 
hippocampus, 
dorsal 
striatum
PLA
Disruptive peptide 
Bidirectional cross-antagonism 
Negative cross-talk 
5HT2a coupling to Gi/o
↑THC physical dependence
↑cognitive deficits associated to THC 
(memory impairment, anxiety, reduced 
social interaction)
(Vinals et al., 2015)
69
activation of mTOR pathway
CB1-A2a Rat striatum Co-IP Cross-antagonism on CB1 
signaling
THC locomotor sensitization
THC reinforcement (CPP)
(Carriba et al., 2007; Ferreira 
et al., 2015; Soria et al., 2004)
Class A-Class A heteromers with potential role in SUD 
Mu-CB1 Rat striatum Electron microscopy Bidirectional negative cross-
talk 
Bidirectional cross-antagonism 
Social play
↓ induced neuroplasticity
(Manduca et al., 2016; Rios et 
al., 2006 ; Rodriguez et al., 
2001)
CB1-CB2 Rat striatum
Activated 
microglia
PLA Bidirectional cross-antagonism
Negative cross-talk
Negative cross-talk in resting 
microglia
Positive cross-talk in activated 
microglia
Bidirectional cross-antagonism
↓ psychostimulant-induced neurotoxicity
neuroinflammation
(Callen et al., 2012)
(Navarro et al., 2018a)
D3/D3nf Rat brain Co-IP ↓ D3 cell surface expression, 
ligand binding 
Impulsivity
Sensitization to cocaine or nicotine
(Karpa et al., 2000; 
Nimchinsky et al., 1997; 
Pritchard et al., 2006; Smith 
et al., 2015)
D1/D3 Rat brain Co-IP co-internalization
positive cross talk on D1 
signaling
↑ Locomotor sensitization to 
psychostimulants
(Fiorentini et al., 2008; 
Marcellino et al., 2008)
D1-H3-sigma1 Rat and 
mouse 
striatum
Co-IP
PLA
Bidirectional cross-antagonism 
Negative cross-talk on D1 
signaling (D1 coupling to 
Gi/o, H3 activation of 
ERK1/2) 
Ex vivo regulation of striatal GABAergic 
activity by acute and chronic cocaine
neuroprotective
(Ferrada et al., 2009; 
Kononoff Vanhanen et al., 
2016; Moreno et al., 2011a; 
Moreno et al., 2014)
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sigma1 mediates cocaine 
disruption of bidirectional 
cross-antagonism and negative 
cross-talk on D1 signaling
A1-A2a Rat striatum Co-IP
Electron microscopy
↓A2a affinity for caffeine Caffeine stimulant effects (Ciruela et al., 2006)
Class A-class C heteromers with a role in SUD
5HT2a-mGlu2 Mouse, 
human cortex
Co-IP
Electron microscopy
Interfering peptide
Modulation of Gi/o-Gq/11 
coupling in favor of Gi/o
Effects of hallucinogens (LSD) (Fribourg et al., 2011 ; 
Gonzalez-Maeso et al., 2008; 
Moreno et al., 2011b; Moreno 
et al., 2012)
A2a-mGlu5 Rat, mouse 
striatum
Expression 
modulated by 
cocaine
Co-IP
PLA
Positive cross-talk ↓ Sensitization to psychostimulants (Beggiato et al., 2016; 
Borroto-Escuela et al., 2017; 
Ferre et al., 2002 ; He et al., 
2016)
M2-GABAb2 Rat cortex Co-IP ↑ M2 signaling Cocaine discrimination (Boyer et al., 2009; Joseph 
and Thomsen, 2017)
GPCR-ion channel heteromers with potential role in SUD
D2- N-type 
Ca2+ channel
Rat striatum Co-IP ↓Channel activity nd (Kisilevsky and Zamponi, 
2008)
D1- N-type 
Ca2+ channel
Rat PFC Co-IP ↓Channel activity nd (Kisilevsky et al., 2008)
ORL1-N-type 
Ca2+ channel
Rat brain Co-IP ↓Channel activity nd (Beedle et al., 2004; Evans et 
al., 2010)
Mu –NMDA 
NR1
Mouse PAG Co-IP Modulation NMDA-CAMKII 
pathway
nd (Rodriguez-Munoz et al., 
2012)
D1-NMDA Rat striatum, 
hippocampus
Co-IP ↑ D1 surface expression
positive cross-talk on D1 
signaling
nd (Fiorentini et al., 2003; Pei et 
al., 2004)




